

Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients

Elizabeth L. Alford, PharmD,^{1,2} James W. Wheless, MD,^{3,4,5} and Stephanie J. Phelps, PharmD^{1,2,3}

¹Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee; ²Center for Pediatric Pharmacokinetics and Therapeutics, Memphis, Tennessee; Departments of ³Pediatrics and ⁴Pediatric Neurology, College of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee; and ⁵Le Bonheur Neuroscience Center and Comprehensive Epilepsy Program, Memphis, Tennessee

Generalized convulsive status epilepticus (GCSE) is one of the most common neurologic emergencies and can be associated with significant morbidity and mortality if not treated promptly and aggressively. Management of GCSE is staged and generally involves the use of life support measures, identification and management of underlying causes, and rapid initiation of anticonvulsants. The purpose of this article is to review and evaluate published reports regarding the treatment of impending, established, refractory, and super-refractory GCSE in pediatric patients.

INDEX TERMS: anticonvulsants, pediatrics, status epilepticus

J Pediatr Pharmacol Ther 2015;20(4):260–289

INTRODUCTION

Generalized convulsive status epilepticus (GCSE) is a common neurologic emergency that represents 1% to 2% of all emergency department visits.¹ Status epilepticus (SE) is traditionally defined as any seizure lasting longer than 30 minutes, whether or not consciousness is impaired or seizures recur without an intervening period of consciousness.² An operational definition that allows for prompt treatment is generally considered to be seizures lasting at least 5 minutes. In reality, the average seizure is less than 2 minutes, and only 40% of seizures lasting 10 to 29 minutes cease without treatment.^{3,4} The definition of GCSE has evolved to include not only the number and duration of seizures but also the number and types of drugs.^{5–7} GCSE can be divided into 4 stages: impending, established, refractory, and super-refractory (Table 1).

Because SE becomes increasingly resistant to anticonvulsant drugs over time, it can be associated with significant morbidity and mortality if not treated promptly and aggressively.⁸ Regardless of patient age, the estimated mortality rate due to GCSE in the United States ranges between

22,000 and 42,000 individuals per year,⁹ with estimated mortality rates as high as 16% in children.¹⁰ This article reviews and evaluates the body of research regarding the treatment of impending, established, refractory, and super-refractory GCSE in pediatric patients.

BASIC SCIENCE OF STATUS EPILEPTICUS

After a single generalized tonic-clonic seizure, there is often a postictal state lasting several minutes, during which the seizure threshold is massively elevated. This change restores homeostasis and prevents runaway excitation. During GCSE, those mechanisms fail and seizures occur in succession or even become self-sustaining. How this occurs is unknown, but recent advances suggest potential explanations. Gamma-aminobutyric acid class A (GABA_A)-mediated inhibition becomes less effective, whereas glutamate's excitatory actions are enhanced.¹¹ This has implications for sequencing anticonvulsant medication during GCSE and for understanding how GCSE progresses to refractory GCSE.

Repeated seizures produce complex pathophysiological and biochemical changes in the

Table 1. Stages of Generalized Convulsive Status Epilepticus from Onset of the Seizure

Stage		Definition
Stage 1 (0-30 min)	Impending GCSE	An acute condition characterized by a continuous seizure lasting at least 5 min, or by 2 seizures without full recovery of consciousness between them
Stage 2 (30-60 min)	Established GCSE	An acute condition characterized by continuous seizures lasting at least 30 min or by 30 min of intermittent seizures without full recovery of consciousness between events
Stage 3 (>120 min)	Refractory GCSE	An acute condition characterized by continuous seizures despite initial treatment with 2-3 AEDs
Stage 4 (>24 hr)	Super-refractory GCSE	An acute condition characterized by seizures that continue for 24 hours or longer after administration of anesthesia, including cases in which SE recurs on reduction or withdrawal of anesthesia

AED, antiepileptic drug; GCSE, generalized convulsive status epilepticus; SE, status epilepticus

brain. Initially, there is release of neurotransmitters and opening and closing of voltage-gated ion channels. Within minutes, receptor trafficking, primarily of the GABA and glutamate receptors, is responsible for a key adaptation that effects medication efficacy. During repetitive seizures, GABA receptors are internalized (moving from the synaptic membrane to the cytoplasm, where they are functionally inactive), and the γ_2 and $\beta_{2,3}$ subunits decrease in number on the synaptic membrane.¹²⁻¹⁵ The γ_2 subunit is associated with sensitivity to benzodiazepines, so their loss on the synaptic surface would result in a time-dependent pharmacoresistance to benzodiazepines. These changes may in part explain the failure of GABA inhibition and the development of pharmacoresistance to benzodiazepines. The potency of benzodiazepines may decrease 20-fold over 30 minutes of SE.^{12,13}

While this maladaptive alteration is occurring, excitatory synapses show changes in the opposite direction from those of GABA synapses. *N*-methyl-D-aspartate (NMDA) receptor subunits are recruited to the synaptic membrane where they form additional receptors that are proconvulsant.^{12,14,16} Other changes in synaptic activity may increase glutamate release. A vicious cycle ensues, whereby loss of inhibition sustains seizure activity, and surface accumulation of NMDA receptors further upsets a breaking mechanism of ongoing seizure activity.

These receptor changes have important implications for treatment, as impending SE (which may be self-limiting) progresses to established and refractory SE. Seizures generate a transient but severe loss of synaptic inhibitory receptors

and peptides, and an increase in synaptic excitatory receptors and peptides. This gives a possible explanation for the tendency of seizures to become self-sustaining and the time-dependent development of pharmacoresistance to GABAergic drugs.¹⁷ This has clinical implications: 1) prehospital treatment for GCSE should be routine as this has the potential of preventing seizure-induced receptor trafficking and pharmacoresistance; 2) in order to avoid time-dependent complications, pharmacoresistance, and brain damage, rapid and vigorous treatment should be administered for GCSE; and 3) increasing seizure activity causes a progressive loss of synaptic GABA receptors; hence, as initial treatment of GCSE, a benzodiazepine should be combined with another drug acting at a different site.¹⁸⁻²⁰

REVIEW OF MANAGEMENT

Standard of Care

The management of GCSE is staged and generally involves the use of life support measures, identification, and management of underlying causes and rapid initiation of anticonvulsant medications (Table 2). Although there have been some randomized controlled trials comparing therapeutic options, our understanding of the management of impending and established GCSE is driven primarily by consensus protocols or guidelines.^{2,21-26} Unfortunately, there are no evidence-based studies or commonly accepted consensus protocols for the management of refractory and super-refractory GCSE; hence, optimal treatment for these stages of GCSE remains unclear.

Table 2. Management of Generalized Convulsive Status Epilepticus

Impending GCSE	Airway	Establish and maintain airway; position the head; aspirate secretions/vomit; apply oropharyngeal tube as needed
	Breathing	Ensure effective ventilation; administer oxygen; ventilate with Ambubag and intubation as needed
	Circulation	Ensure venous access; monitor vitals signs (HR, RR, BP, O ₂ saturations); maintain blood pressure
	Temperature	Treat fever with rectal acetaminophen, 15-20 mg/kg, and/or a cooling blanket
	Labs	Determination of glucose and electrolyte levels (including Ca and Mg), complete blood count, renal and hepatic function tests, toxicological screening, and anticonvulsant drug serum concentrations may be indicated. If infection is suspected, blood cultures, lumbar puncture, and urinalysis may be needed.
	Therapies	<ul style="list-style-type: none"> • Empiric administration of dextrose 50%. • Adolescents: empirical administration of thiamine, 100 mg, before dextrose in those at risk for Wernicke's encephalopathy
	AED	<p>Out of hospital</p> <ul style="list-style-type: none"> • Midazolam (IN): 0.15-0.3 mg/kg • Midazolam (buccal): 0.15-0.5 mg/kg • Midazolam (IM): 0.2 mg/kg • Diazepam (PR): 0.5 mg/kg (2-5 yr); 0.3 mg/kg (6-11 yr); 0.2 mg/kg (≥12 yr) <p>In ED or hospital</p> <ul style="list-style-type: none"> • Lorazepam (IV): 0.1 mg/kg (maximum dose 10 mg) over 30-60 sec; if seizure continues in 5 min, give an additional 0.1 mg/kg • Midazolam (IM): 0.2 mg/kg • Midazolam (IN): 0.3 mg/kg
Established GCSE	AED	<p>First-line</p> <ul style="list-style-type: none"> • Phenytoin (IV): 18-20 mg/kg over 20 min (<1 mg/kg/min; maximum, 50 mg/min); may give an additional 5 mg/kg as needed • Fosphenytoin (IV or IM): 18-20 mg PE/kg (<3 mg PE/kg/min; maximum <100-150 mg PE/min) <p>Second-line</p> <ul style="list-style-type: none"> • Phenobarbital (IV): 15-20 mg/kg over 20 min (<100 mg/min) • Valproate (IV): 25-30 mg/kg over 5-15 min (<3 mg/kg/min up to 200 mg/min) followed by an infusion of 1-6 mg/kg/hr <p>Third-line</p> <ul style="list-style-type: none"> • Lacosamide (IV): 50-400 mg; 200 mg given over 15 min • Levetiracetam (IV): 40-60 mg/kg, maximum 3,000 mg (administer 2-5 mg/kg/min)
Refractory GCSE	Monitoring	<ul style="list-style-type: none"> • Implement continuous EEG monitoring • Ensure patient is normovolemic • Ensure cerebral perfusion pressure is >70 mm Hg • Administer volume as needed and begin vasopressors to achieve adequate mean arterial pressure (>120 mm Hg) • Consider administration of pyridoxine, magnesium sulfate, and IVIG
	AED	<p>First-line</p> <ul style="list-style-type: none"> • Midazolam: 0.2-0.4 mg/kg (maximum dose 10 mg) bolus at a rate of 2 mg/min, followed by 0.05-2 mg/kg/hr • Pentobarbital: 10-20 mg/kg bolus at a rate of ≤50 mg/min followed by 1-5 mg/kg/hr (if hypotension occurs, slow the rate of delivery or add vasopressors) • Propofol: 1-2 mg/kg bolus followed by <4 mg/kg/hr in children; larger dose may be used in adolescents

AED, anti-epileptic drug; BP, blood pressure; ECG, Electrocardiogram; ED, emergency department; EEG, electroencephalogram; HR, heart rate; IM, intramuscular; IN, intranasal; IV, intravenous; IVIG, IV immunoglobulin; PE, phenytoin equivalents; PR, rectal; RR, respiratory rate

The initial management of GCSE includes securing an airway and monitoring vital signs, especially blood pressure. Arterial blood pressure should remain above 120 mm Hg as cerebral blood flow is dependent upon systemic pressure; pressures of <90 mm Hg must be avoided as a decrease in oxygen and glucose may result in neurologic injury. The patient's temperature should be monitored and fever treated aggressively. Febrile GCSE is most common in pediatric patients, and normalization of body temperature helps minimize neurologic morbidity. Intravenous (IV) access should be established. When IV access is not possible, intraosseous administration may be considered.

Laboratory studies of serum glucose and electrolyte levels (including calcium and magnesium), complete blood count, and renal and hepatic function tests should be performed. Anticonvulsant serum concentration should be obtained as needed, and a urine drug screen should be performed if there is suspicion of ingestion. If infection is suspected, blood cultures, lumbar puncture, and urinalysis may be needed. Antibiotic administration does not need to wait until after the lumbar puncture if the patient is medically unstable.

Patients should be given dextrose 50% as empirical therapy in the event they are hypoglycemic. Adolescents, or those at risk for Wernicke's encephalopathy, should be given 100 mg of thiamine before dextrose is administered. Patients with refractory GCSE also should undergo arterial blood gas and continuous electroencephalogram (EEG) monitoring.

Impending GCSE

Impending GCSE is characterized by continuous generalized seizures lasting at least 5 minutes or 2 seizures without full recovery of consciousness between events (Table 1). Impending GCSE may terminate spontaneously or may respond to a benzodiazepine (BDZ). Benzodiazepines are the preferred therapy for this stage, but the specific chemical entity used will depend on formulation availability and route of administration.

The anticonvulsant effect of BDZs is related to GABA inhibition that occurs as a direct result of binding to the GABA_A receptor (Figure). This increases the frequency of channel opening to produce a surge in chloride conductance, which causes the cell to become less responsive to excit-

atory inputs. This effect occurs at serum concentrations achieved by doses used in clinical practice. Animal data suggest that the pharmacologic effect of a benzodiazepine is altered by prolonged seizures; hence, efficacy is changed when therapy is delayed. The mechanisms for these functional changes involve alterations in the cellular expression of GABA_A receptors, which undergo a rapid internalization during SE. Changes in excitatory neurotransmission may also underlie the alterations that make prolonged GCSE less responsive to benzodiazepines. A direct effect on voltage-gated sodium channels is also suspected.

Historically, the discussion of management has centered on which BDZ to use as first-line therapy in patients in the emergency department, diazepam (DZP) or lorazepam (LZP).^{21,23,24,27-30} Although some consensus guidelines suggest either agent is acceptable,³¹ most recommend IV LZP as the initial treatment of choice.^{2,21,23-25,27-29} More recent studies have investigated the use of intranasal³²⁻³⁵ or buccal³⁶ BDZs in the emergency department (Table 2).

Research has begun to focus on novel methods of BDZ administration in the outpatient setting. The Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) was a double-blind randomized trial that compared intramuscular (IM) midazolam (MDL) to IV LZP.^{37,38} Investigators found that IM MDL, given by paramedics using an autoinjector, was more likely to terminate seizures prior to arrival at the emergency department than IV LZP. The authors also noted that patients who received IM MDL required fewer other rescue therapies and were unlikely to require hospitalization or intensive care unit admission. As expected, time to administration of the first dose of BDZ was shorter with IM administration (1.2 vs. 4.8 minutes, respectively), but cessation of seizure activity after administration was quicker with IV administration (1.6 vs. 3.3 minutes, respectively). The authors concluded that IM MDL is the best option for treatment of impending SE in the emergency department setting.

Diazepam given IM using an autoinjector was also investigated in a 2-part phase III trial.^{39,40} The first part was a randomized, double-blind, parallel group, placebo-controlled multicenter study (n=234) that found a longer time to next seizure or rescue in the DZP autoinjector group compared to the placebo autoinjector group (haz-




Figure	Mechanism	Anticonvulsant
1	VG-Na ⁺ Channel	Carbamazepine, Eslicarbazepine acetate, Felbamate, Lamotrigine, Oxcarbazepine, Phenytoin, Pregabalin, Topiramate, Valproate, Zonisamide
2a	VG-Ca ²⁺ Channel (L-type)	Gabapentin, Pregabalin
2b	VG-Ca ²⁺ Channel (T-type)	Ethosuximide, Topiramate, Valproate, Zonisamide
2c	VG-Ca ²⁺ Channel (N + P type)	Lamotrigine
3	GABA _A receptor (agonist)	Barbituates, Benzodiazepines, Felbamate, Topiramate
4	GABA _A	Propofol
5	GABA uptake inhibitor	Tiagabine
6	GABA-transaminase inhibitor	Vigabatrine
7	GAD modulation	Gabapentin, Valproate
8	SV2A	Levetiracetam
9a	AMPA, kainate receptor	Phenobarbital, Topiramate
9b	AMPA, non-competitive antagonist	Perampanel
10	NMDA receptor	Felbamate, Ketamine, Propofol, Magnesium

AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; Ca²⁺, calcium; GAD, glutamic acid decarboxylase; Na⁺, sodium; NMDA, N-methyl-D-aspartate receptor; SV2A, synaptic vesicle glycoprotein 2A; VG, voltage-gated

Figure. Sites of action of antiepileptic drugs used in the treatment of status epilepticus.

ard ratio: 0.55; 95% confidence interval: 0.34-0.88; p=0.012).³⁹ The second part was an open-label continuation study (n=129; 1380 treatments) that assessed the long-term safety and effectiveness of DZP autoinjector for acute repetitive seizures.⁴⁰ That study found that 77.6% of cases either had no seizure or did not require rescue treatment

in the 12 hours after administration of DZP by autoinjector. The most common treatment-emergent adverse events were pain, hemorrhage, and bruising at the injection site; however, none of the events was considered severe or clinically significant.

Recent studies have focused on aborting im-

pending SE through transmucosally delivered BDZs when IV and/or IM administration may be difficult or impossible (e.g., home setting, extended care, paramedic attendance). Benzodiazepines may be given via rectal (PR),^{34,35,41-45} intranasal (IN),^{32-35,44-57} and buccal^{36,41,42,52,58-62} routes (Table 3).

Rectal absorption of DZP is rapid but varies significantly (50%-100%) due to first-pass metabolism.⁶³ Although a kit for rectal administration of DZP is commercially available (Diastat; Valeant Pharmaceuticals, Bridgeville, NJ), medication errors have been reported due to failure to properly dial and lock the prescribed dose. Compared to PR BDZ administration, IN administration results in higher serum concentrations, faster onset of action, and more effective seizure control.^{34,35,49} All studies have concluded that IN MDL is more effective than PR DZP and that it is convenient, easier to use, and as safe as PR DZP. Buccal and sublingual routes also bypass gastric and hepatic first-pass metabolism, but bioavailability can be incomplete as the drug is often swallowed. Successful administration via this route in a patient with GCSE is also unlikely due to muscular contractions of the jaw and clenching of teeth and/or patient secretions that can be associated with seizures.

The IN route is being used in virtually all settings; however, use in the home setting is complicated by the lack of a commercially available kit for IN use and difficulties finding a pharmacy willing to dispense a schedule 4 control substance injectable product for a non-parenteral route. MZL and LZP readily cross the nasal mucosa and blood-brain barrier to produce a rapid rise in both serum and cerebrospinal fluid concentrations.^{55,64} In fact, sera concentrations are comparable to those noted following IV injection.^{55,65} Rey et al⁵⁴ evaluated the pharmacokinetics of IN and IV MDL in 12 children (1-5 years old) given 0.2 mg/kg and found that the half-life was similar (2.2 hours IN vs. 2.4 hours IV). The apparent plasma clearance and volume of distribution after IN administration were approximately 2 times greater than that observed after IV delivery. Intranasal LZP has also been investigated. The lag time for IN was less than that noted for buccal administration (0.6 ± 1.6 minutes versus 2.6 ± 2.7 minutes, respectively).⁵⁵ The time to maximum concentration was also faster for IN administration (105 ± 75 minutes) than buccal delivery (161 ± 47 minutes).

The efficacy of IN MDL has been demon-

strated in the pediatric population.^{32-35,44-50,53} Clinical trials have compared the safety and efficacy of IN MDL to those of IV DZP^{33,48,50} and PR DZP.^{34,35,45,49} Several studies have also evaluated buccal administration of MDL versus that of PR DZP.^{41,59,60,66,67} All studies preferred IN or buccal MDL for use in the community,^{49,62,67} emergency medical system/paramedics,^{43,45} and emergency department settings.^{32,34-36,50,59,61} When medication is given IN, one should consider using a mucosal atomizing device.

Historically, IV LZP has been the agent of choice in impending GCSE in the emergency department or hospital setting; however, studies have attempted to address the role of IN BDZs (Table 3).^{32-35,45,47-50,53,56,57,62} Lahat et al³² prospectively compared IN MDL (0.2 mg/kg) to IV DZP (0.3mg/kg) in 47 children (6 months-5 years of age) whose seizures lasted 10 minutes or longer. The 2 routes of administration were equally effective, stopping seizures in 88% (IN) and 92% (IV) of patients. The mean time from hospital arrival to starting treatment was shorter in the IN group (3.5 ± 1.8 minutes vs. 5.5 ± 2.0 minutes, respectively), allowing for faster seizure cessation with IN MDL (6.1 vs. 8 minutes, respectively).

A similar study by Mahmoudian and Zadeh⁴⁸ compared the efficacy of IN MDL (0.2 mg/kg) to that of IV DZP (0.2 mg/kg) in 70 patients (2 months to 15 years of age) seen in the emergency department for seizures. Both of the methods were equally effective, and no adverse effects occurred. The mean time to seizure control following medication administration was 3.58 ± 1.68 minutes (IN MDL) and 2.94 ± 2.62 minutes (IV DZP).

Thakker and Shanbag⁵⁰ conducted a randomized, controlled study in a pediatric emergency department of a tertiary general hospital, which compared the safety and efficacy of IN MDL (0.2 mg/kg) to that of IV DZP (0.3 mg/kg) in 50 children (1 month to 12 years of age) with acute seizures lasting at least 10 minutes. Overall, 75% of seizures were controlled with IN MDL compared to 65.2% with IV DZP. The mean time between arrival at hospital and anticonvulsant administration was significantly shorter with IN MDL (3.37 ± 2.46 minutes vs. 14.13 ± 3.39 minutes, respectively). Once the medication was given, the mean time to control of seizures was shorter with IV DZP (2.67 ± 2.31 minutes) than with IN MDL (3.01 ± 2.79 minutes). No significant

Table 3. Use of Intranasal Benzodiazepines for Seizure Cessation in Pediatric Patients

Reference	Study Type (n)	Setting	Age	Intranasal BZD: Dose	Comparator	Seizure Cessation	ADRs with Intranasal
Arya ⁵⁶	Randomized, open-label (n=141)	ED	6 to 14 yr	LZP: 0.1 mg/kg (maximum of 4 mg)	IV LZP	83.1% (IN) vs. 80% (IV) within 10 min	Assisted ventilation required (n=1)
Bhattacharyya ³⁵	Prospective, randomized, controlled, single blinded (n=188 episodes, 46 children)	ED, clinic	3 mo to 12 yr	MDZ: 0.2 mg/kg	PR DZP	116.7 sec (IN) vs. 178.6 sec (PR), p=0.005	None observed
Figsin ⁵⁷	Prospective, open-label (n=16)	ED, hospital	2 mo to 14 yr	MDZ: 0.2 mg/kg	None	81.3% success rate	Tachypnea and tachycardia (n=1); bradypnea (n=1)
Figsin ³⁴	Prospective, randomized (n=45)	ED	1 mo to 13 yr	MDZ: 0.2 mg/kg	PR DZP	87% (IN) vs. 60% (PR) within 10 min	Tachypnea (n=1), tachycardia (n=1)
Holsti ⁴⁹	Retrospective (n=57)	EMS	8 mo to 16 yr	MDZ: 0.2 mg/kg	PR DZP	25 min (IN) vs. 45 min (PR), p=0.003	*
Holsti ⁴⁵	Prospective, randomized (n=92)	Home	Median: 5.6 yr (IN), 6.9 yr (PR)	MDZ: 0.2 mg/kg	PR DZP	3 min (IN) vs. 4.3 min (PR), p=0.09	Required intubation (n=1)
Kutlu ⁴⁷	Prospective, open-label (n=9)	ED, clinic	6 mo to 9 yr	MDZ: 0.3 mg/kg	None	100% success rate; n=1 second dose	Respiratory depression (n=1)
Lahat ³²	Prospective, open-label (n=20)	ED	6 mo to 16 yr	MDZ: 0.2 mg/kg	None	3.5 min (2.5-5 min); 95% success rate	*
Lahat ³³	Prospective, randomized (n=47)	ED	6 mo to 5 yr	MDZ: 0.2 mg/kg	PR DZP	3.5 min (IN) vs. 5.5 min (PR)	None observed
Mahmoudian ⁴⁸	Prospective, randomized (n=70)	ED	2 mo to 15 yr	MDZ: 0.2 mg/kg	IV DZP	3.58 min (IN) vs. 2.94 min (IV), p = 0.007	None observed
Scheepers ⁵³	Prospective, open-label (n=22, 84 treatments)	Hospital	12 to 72 yr	MDZ: 5 mg (<50 kg), 10 mg (>50 kg)	None	94% success rate	None observed
Thakker ⁵⁰	RCT (n=50)	ED	1 mo to 12 yr	MDZ: 0.2 mg/kg	IV DZP	6.67 min vs. 17.18 min after arrival; 2.67 min vs. 3.01 min after drug	None observed

ADR, adverse drug reaction; BZD, benzodiazepine; DZP, diazepam; ED, emergency department; EMS, emergency medical services; IN, intranasal; IV, intravenous; LZP, lorazepam; MDZ, midazolam; PR, rectal; RCT, randomized controlled trial

*Not mentioned in the report or unknown.

side effects were observed in either group.

Arya et al⁵⁶ conducted a randomized, open-label trial comparing the efficacy and adverse effects of IN LZP with that of IV LZP in 141 children (6-14 years of age) who presented consecutively to their hospital with acute seizures. After children were stabilized in the emergency department, they were randomized to receive either IN (n=71) or IV (n=70) LZP (0.1 mg/kg, maximum 4 mg). The primary outcome was clinical seizure remission within 10 minutes of drug administration, which occurred in 83.1% (IN) and 80% (IV) of patients. All studies comparing IN with IV BDZ have reported similar efficacy, but remission was accomplished within a shorter time using IN administration. Although most practitioners will continue to consider IV LZP the agent of choice in the emergency department, it is very likely that an IN BDZ will become the standard of practice due to ease and quick administration.

Because the dose must be administered using a 100- to 200- μ L spray or solution, the IN route can only be used for drugs that are highly concentrated and have good aqueous solubility.^{68,69} Although most reports have used a variety of delivery systems (e.g., drops, sprays, and atomization devices), the lack of standardization in delivery has not impacted efficacy and tolerability outcomes. Effective delivery is best achieved by distributing the drug as a mist rather than as larger droplets that may aggregate and run out of the nose or down the back of the throat, rendering it ineffective. Placing half the dose into each nostril can double the surface area available for absorption. Upper airway infections, extent of nasal mucosa irritation, and differences in the amount of spray that is swallowed may all impact absorption. However, variability in the amount absorbed after nasal administration should be comparable to that after oral administration.

Established GCSE

Established GCSE occurs when a BDZ fails to terminate seizures (Table 1). This is characterized by at least 30 minutes of continuous seizures or 30 minutes of intermittent seizures without full recovery of consciousness between seizure events. Management generally involves administration of phenytoin (PHT), fosphenytoin (fPHT), phenobarbital (PB), or valproate (VPA). Recently, levetiracetam and lacosamide also have been used, especially during times of medication

shortages that have rendered traditional drugs unavailable. Most guidelines recommend giving either PHT/fPHT^{2,21-23,25,26,31} or PB^{2,24,25} after a full dose of BDZs has failed (Table 2), but there is little level 1 evidence to support that practice.

Phenytoin

For over 75 years, numerous studies have attempted to elucidate the mechanism of action of phenytoin. Studies have noted that it influences ion conductance, Na/K-ATPase activity, post-tetanic potentiation, calcium systems, and neurotransmitter release (Figure). The major antiseizure effect is due to inhibition of voltage-dependent sodium channels. Phenytoin works on the intracellular part of the ion channel to decrease the influx of sodium into neurons and thereby decreases excitability (Figure). Activity is use- and concentration-dependent; hence, the onset of action should occur as soon as an effective concentration is achieved. At serum concentrations obtained in clinical practice, phenytoin does not modify response to pre- or postsynaptic GABA, nor does it impact NMDA or alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.

Although a hydantoin has historically been used as the first-line agent in established GCSE, there is little evidence to support the fact that it is as effective as PB. Recent studies comparing IV PHT/fPHT to other agents will be detailed in later sections. If IV access cannot be obtained and IM administration is undesirable, PHT or fPHT can be given via the interosseous (IO) route. Dosing recommendations for IO administration are derived from a prospective, controlled, randomized porcine study comparing plasma drug concentrations and pharmacodynamics of IV versus IO fPHT, 20 mg PE/kg, with those of PHT, 20 mg/kg.⁷⁰ Significantly higher free and total PHT concentrations were found with IO administration of fPHT at 0 to 10 minutes ($p < 0.05$) and 0 to 20 minutes after infusion ($p < 0.05$). There were no significant differences for either medication beyond 20 minutes. Therefore, the authors concluded that PHT should be given IO at the standard dose of 20 mg/kg, and if fPHT is used, a slower infusion rate may be needed to avoid initial supratherapeutic concentrations.⁷⁰

Phenobarbital

PB binds to inhibitory GABA_A receptors at the

beta subunit to increase the duration of chloride ion channel opening, thereby potentiating the effect of GABA at this receptor (Figure). At high serum concentrations, PB can activate the GABA_A receptor directly to inhibit calcium-dependent release of neurotransmitters. Importantly, prolonged seizure activity does not alter the effectiveness of PB at the GABA_A receptor as it can inhibit this receptor in the absence of GABA. Phenobarbital also inhibits glutamate-activated sodium and calcium channels at the AMPA receptor to reduce the release of glutamate. This mechanism requires higher concentrations than those needed to produce an effect on GABA. PB has no effect on voltage-gated sodium channels.

Only 2 randomized, controlled trials^{71,72} have attempted to determine whether PHT or PB should be used in established GCSE; however, only 1 of those studies⁷¹ included pediatric patients. Shaner et al⁷¹ prospectively compared PB to DZP plus PHT in 36 children (18 in each group) with established GCSE. In the first group, PB was given IV at a dose of 20 to 30 mg/kg. Patients in the second group received IV doses of DZP as small as 2 mg and as large as 20 mg plus a PHT loading dose (range: 6-21 mg/kg) that was based on the patient's admission serum PHT concentration. The authors concluded that PB was rapidly effective and comparable in safety to DZP plus PHT.

Although it is impossible to determine whether DZP was responsible for efficacy in the DZP/PHT group, the study by Treiman et al⁷² would suggest that might be the case. That study is the largest randomized, controlled trial to date, in which 384 adult patients with established GCSE received either IV LZP (0.1 mg/kg), PB (15 mg/kg), DZP (0.15 mg/kg) plus PHT (18 mg/kg), or PHT alone (18 mg/kg). LZP successfully stopped seizures in 64.9% of patients compared to 58.2%, 55.8%, and 43.6% of patients given PB, DZP/PHT, or PHT alone, respectively. The trial findings noted that DZP/PHT was more effective than PHT as monotherapy. When patients with established and refractory GCSE were combined in a post hoc analysis, the differences between PB and PHT as monotherapies approached significance, with PB being superior. This is an important finding in light of the low dose of PB that was used in the trial.

Recently Yasiry et al⁷³ reported the effectiveness of 4 anticonvulsants (i.e., levetiracetam, PB, PHT,

and VPA) in the treatment of BDZ-resistant convulsive SE, using meta-analysis of 27 published studies. Evidence did not support the first-line use of PHT. Efficacy data for PB (remission: 73.6% [95% confidence interval [CI]: 58.3-84.8%]), VPA (remission: 75.7% [95% CI: 63.7-84.8%]), and levetiracetam (68.5% [95% CI: 56.2-78.7%]) supported their use as first-line therapy in BDZ-resistant SE.

Valproic Acid

Although the precise mechanism of action is not known, several mechanisms have been suggested. VPA may potentiate postsynaptic GABA, inhibit GABA-transaminase and succinic acid decarboxylase, and/or increase glutamic acid decarboxylase. It may also block voltage-gated sodium channels to limit depolarization-induced, sustained repetitive firing and may block low-threshold T-type calcium channels (Figure).

Many consensus guidelines also recommend the use of VPA as an alternative second-line treatment.^{21,24,25,31} Reports in adults⁷⁴⁻⁷⁹ and pediatric patients⁷⁸⁻⁸³ with SE unresponsive to first-line agents have generally noted successful termination of seizures following IV VPA (Table 4).

To date, there have been 3 retrospective reports of IV VPA in pediatric patients.⁸⁰⁻⁸² Hovinga et al⁸⁰ successfully used IV VPA in 2 pediatric patients with GCSE who failed to respond to BDZ, PB, PHT, and pentobarbital (PTB). Both of the patients were successfully treated with a loading dose of 20 mg/kg followed by a maintenance infusion of 4 to 6 mg/kg/hr. Uberall et al⁸¹ evaluated IV VPA (loading dose of 20-40 mg/kg followed by 5 mg/kg/hr) in 41 children who did not respond to DZP, PB, or PHT therapy. VPA stopped clinical and bioelectric seizures in 78% of all types of SE but was effective in 90% of patients with GCSE. Yu et al⁸² conducted a retrospective review of the use of IV VPA in 40 pediatric patients (1 month to 19 years of age) with either multiple types of SE (n=18) or acute repetitive seizures (n=22). Patients who were naïve to VPA received a loading dose of 25 mg/kg with an average infusion rate of 2.8 mg/kg/hr. Seizures stopped within 20 minutes in 100% of patients with SE and in 95% of those with acute repetitive seizures.

Two prospective evaluations of IV VPA for seizure control in pediatric patients also have been published.^{79,83} Chen et al⁷⁹ evaluated VPA in 48 adult and pediatric patients with convulsive

Table 4. Use of Valproate in Pediatric Patients With Status Epilepticus Unresponsive to Benzodiazepines

Reference	Study Type (n)	Age	VPA Dose	Comparator	Seizure Cessation	ADRs
Agarwal ⁷⁸	Prospective, randomized (n=100)	27.4 ± 16.8 yr (group A), 27 ± 15.1 yr (group B)	20 mg/kg	PHT: 20 mg/kg	Success rate 88% vs. 80%; p<0.05	Mild LFT elevation (n=4)
Chen ⁷⁹	Prospective, observational (n=48)	2 to 79 yr	15 mg/kg bolus, then 6 mg/kg/hr	None	Success rate 87.5%	None observed
Mehta ⁸³	Open-label RCT (n=40)	5 mo to 12 yr	30-40 mg/kg	DZP: 10-80 mcg/kg/min	8.8 vs. 26.6 min; p=0.001	None observed
Uberall ⁸¹	Retrospective (n=41)	0 to 16.1 yr	20-40 mg/kg, then 5 mg/kg/hr	None	Success rate 78%	None observed
Yu ⁸²	Retrospective (n=40)	1 mo to 19 yr	25 mg/kg, then 3 mg/kg/min	None	Success rate 95.5%	Transient tremor (n=1)

ADR, adverse drug reaction; DZP, diazepam; LFT, liver function tests; PHT, phenytoin; RCT, randomized controlled trial; VPA, valproic acid

SE for whom IV DZP and IM PB failed. Five of the patients given VPA were <5 years of age, and the youngest was 2-years-old. Patients received a loading dose of 30 mg/kg that was followed by 6 mg/kg/hr. Seizures stopped in 87.5% of patients within 1 hour of administration. Mehta et al⁸³ randomized 40 children to receive either IV VPA or continuous infusion DZP. There were no significant differences in efficacy (80% VPA vs. 85% DZP); however, there were differences in the median time to control seizures (5 minutes with VPA vs. 17 minutes with DZP).

Several studies have compared IV VPA to PHT.^{78,84-86} Misra et al⁸⁴ compared IV VPA, 30 mg/kg (n=35) to PHT, 18 mg/kg (n=33) as the first-line agent in a randomized, prospective, head-to-head open study. Benzodiazepines were not given, and most of the patients were adults. Valproate was significantly more effective (66%) than PHT (42%). As a second choice in patients unresponsive to the first agent (i.e., cross-over), VPA was also more effective than PHT (79% vs. 25%, respectively). Tiamkao et al⁸⁵ also retrospectively evaluated VPA (n=37) and PHT (n=17) as first-line agents in patients older than 15 years of age. All but 1 patient received 10 mg of IV DZP. The mean IV loading dose of PHT (743 ± 116 mg) was followed by 300 mg/day, and the mean IV loading dose of VPA (1000 ± 239.14 mg) was followed by 1200 mg/day. There were no significant differences between the PHT and VPA groups in all outcome variables. Chitsaz et al⁸⁶ also compared VPA (20 mg/kg followed by 1 mg/kg/hr) with PHT (20 mg/kg with supplemental 10 mg/kg if needed, followed by 4.5 mg/kg/day) in a predominantly adult population for whom IV DZP had failed. There were no significant differences in response within the first 12 hours (73.3% vs. 60%, respectively; p=0.06). In a randomized study, Agarwal et al⁷⁸ compared IV PHT (n=50) with IV VPA (n=50) in patients with SE refractory to BDZs and found no differences in efficacy (88% vs. 84%, respectively). In patients younger than 18 years of age, seizures stopped in 20 of 22 patients (91%) given VPA and 12 of 16 patients (75%) given PHT. The authors concluded that there were no differences in seizure recurrence at 12 hours regardless of age.

Only one study has compared VPA (n=30) with PB (n=30).⁸⁷ VPA was given via rapid IV loading, which was defined as 5 to 6 mg/kg/min over 5 to 10 minutes. VPA, in doses of 20 mg/

Table 5. Newer Agents Used in Pediatric Cases of Established Status Epilepticus

Reference	Study Type (n)	Age	Drug and Dose	Outcome	ADRs
Abend ⁹⁴	Case series (n=10)	0.08 to 14 yr	LEV: 6.5-31 mg/kg	Seizure reduction \geq 75% in all patients	None observed
Goraya ⁹³	Case series (n=10; n=4 with SE or ARS)	3 wk to 16 yr	LEV: 29-115 mg/kg/day	Cessation (n=3); reduced frequency (n=1)	None observed
Kirman ⁹⁵	Retrospective (n=32; n=16 with SE)	2 mo to 18 yr	LEV: 50 mg/kg, then 25 mg/kg every 12 hr	100% response rate	None observed
McTague ⁹⁷	Prospective, observational (n=51; n=45 with SE or ARS)	0.2 to 18 yr	LEV: 5-30 mg/kg	64% response rate	Aggressive behavior (n=3)
Standish ⁹⁶	Retrospective (n=20)	0 to 16 yr	LEV: 16-98.8 mg/kg	75% seizure cessation	Irritability, agitation (n=3); vomiting (n=1)
Jain ¹⁰⁰	Case series (n=3)	12 to 17 yr	LAC: 2-2.5 mg/kg	Single dose response (n=2); 2 doses required (n=1)	Chorea (n=1), oculogyric crisis (n=1)
Shiloh-Malawsky ⁹⁹	Case report	8 yr	LAC: 25 mg twice daily	Complete resolution (clinical and EEG) after 5 days	*

ADR, adverse drug reaction; ARS, acute repetitive seizures; EEG, electroencephalogram; LAC, lacosamide; LEV, levetiracetam; SE, status epilepticus

*Not mentioned in the report or unknown.

kg, successfully terminated GCSE within 20 minutes in 90% of children compared to 77% of children given IV PB, 20 mg/kg (p=0.189). Clinically significant adverse effects occurred in 74% of the PB group and 24% of patients in the VPA group (p<0.001).

Brigo et al⁸⁸ used 5 randomized, controlled trials to perform a meta-analysis comparing the efficacy and safety of VPA, PB, and PHT in GCSE.⁸⁸ They reported that VPA and PHT have similar efficacy as VPA and PB; however, VPA had a better safety profile than either PHT or PB. Because many of the studies were underpowered, there was insufficient evidence to support a change in clinical practice. That group also conducted a second meta-analysis comparing IV VPA with PB.⁸⁹ Again, both agents had comparable efficacy, but VPA had a better safety profile.

Levetiracetam

Historically, levetiracetam was used only in cases of super-refractory SE. In recent years, it has been used earlier due to medication shortages that have made conventional drugs unavailable. Levetiracetam has no effect on voltage-gated Na channels or GABAergic transmission and no affinity for either GABAergic or glutamatergic receptors (Figure). The drug has recently been noted to bind to a presynaptic vesicle glycoprotein (sv2A) that has been proposed to act as a transporter for presynaptic P/Q type voltage-dependent calcium ([Ca²⁺]_c). This is considered an important second messenger system in neurons, which might contribute to its unique mechanism of action. Levetiracetam has also been noted to reduce neurotransmitter release by inhibiting presynaptic L-type calcium channels.

Levetiracetam has been considered a potentially useful agent for SE due to its few adverse effects, limited drug interactions, and ease of IV administration compared to other IV anticonvulsants. Early investigations of levetiracetam for SE used the oral formulation and found it to be effective for various types of SE and well tolerated by patients.⁹⁰⁻⁹² There are 5 published case series of the use of IV levetiracetam for SE in the pediatric population (Table 5).⁹³⁻⁹⁷

One retrospective analysis included 4 children who received IV levetiracetam for acute repetitive seizures or SE in doses as large as 115 mg/kg/day and as small as 29 mg/kg/day.⁹³ Three of 4 patients had seizure termination; the fourth patient had a reported decrease in seizure frequency. Another retrospective case series noted that 8 of 10 critically ill pediatric patients with SE or acute repetitive seizures responded and that the other 2 children exhibited a reduction of seizures (levetiracetam IV loading dose ranged from 6.5 to 31 mg/kg).⁹⁴ Kirmani et al⁹⁵ reported a retrospective study of 32 patients treated with an IV loading dose of levetiracetam (25 of 32 patients received 50 mg/kg; range: 25-70 mg/kg), and 16 of those patients received treatment for SE. All patients responded both clinically and according to EEG monitoring. The rate of seizure cessation using IV levetiracetam for patients with SE was determined in a case series by Standish et al.⁹⁶ The seizure cessation rate was 75% (15 of 20 patients) with a mean dose of 37.5 mg/kg (range: 16-98.8 mg/kg). Three patients experienced adverse events of behavioral side effects, 1 of whom was treated with pyridoxine. An observational study of 45 patients (mean 7.1 years of age) with acute repeated seizures or SE were initially treated with 5 to 30 mg/kg levetiracetam IV.⁹⁷ A total of 29 patients responded to the treatment, and 3 patients displayed aggressive behavior as a side effect of the medication. These case series suggest that IV levetiracetam seems to be safe and effective for the termination of SE when first-line agents fail to control the seizure. When levetiracetam is used, the patient should be given a loading dose of 40 to 60 mg/kg (maximum 3000 mg) at a rate of 2 to 5 mg/kg/min.

Lacosamide

Like levetiracetam, lacosamide also has been used in pediatric patients for the treatment of SE (Table 5). A review paper published in 2013 found 19 publications, including 10 case reports and 9 case series, reporting IV lacosamide for the treatment of SE.⁹⁸ The review cited 1 pediatric case report⁹⁹ and 1 pediatric case series.¹⁰⁰

The case report⁹⁹ involved an 8-year-old boy with new onset seizures that progressed to refractory SE, which was treated successfully with enteral lacosamide, 25 mg twice daily. This success came after attempting the following treatments over a 10-week period: combinations of PHT,

levetiracetam, PB, topiramate, felbamate, and VPA; propofol (PRO), PTB, MDL, and ketamine to induce EEG burst suppression; ketogenic diet; high-dose corticosteroids; IV immunoglobulin (IVIG); plasmapheresis; and vitamin B₆, folic acid, carnitine, and biotin.

The case series (n=3) described the successful implementation of lacosamide in pediatric patients (12-17 years of age) with refractory tonic SE.¹⁰⁰ After 3 or more standard anticonvulsants were tried over the course of 8 to 29 hours, an IV loading dose of lacosamide (2-2.5 mg/kg) was given. Two patients responded to a single dose, and 1 patient required 2 doses of lacosamide.

Adverse effects

Generally, the hesitation to use a hydantoin or barbiturate has not been based on their effectiveness as an anticonvulsant but upon potential adverse effects. The vasodilatory and cardio-depressant effects of PB may cause profound hypotension and hypopnea. The respiratory depressant effects are compounded when used in conjunction with a BDZ. Interestingly, Treiman et al⁷² noted no differences in incidence of adverse effects between adults given IV PB and those given DZP plus PHT.⁷² Among 91 patients treated with PB, 12 patients (13.2%) experienced hypoventilation, 31 (34%) showed hypotension, and 3 (3.3%) had cardiac arrhythmias; among the 101 patients receiving PHT, 10 patients (9.9%) experienced hypoventilation, 27 (26.7%) showed hypotension, and 7 (6.9%) had cardiac arrhythmia. Shaner et al⁷¹ noted that when the serum concentration of PB exceeded 70 mg/L, the level of consciousness was almost always impaired. That said, 83% of patients with overt SE in the study by Treiman et al⁷² had not fully regained consciousness 12 hours after administration of any anticonvulsant; hence, consideration of sedation may not be as important in selecting an agent.

When given in large doses and by rapid infusion, VPA rarely causes cardiovascular toxicity such as hypotension or dysrhythmia.^{24,74,75,81,82} It has not been noted to cause respiratory depression, and it does not cause sedation.^{75,82} However, VPA can cause coagulopathies such as platelet dysfunction, thrombocytopenia, and hypofibrinogenemia.^{101,102} Acute encephalopathy after IV VPA was reported in a 45-year-old patient with non-convulsive SE.¹⁰³ Although rare, pancreati-

tis has been noted with VPA. Both PB and PHT contain a polypropylene solvent that may cause local irritation, necrosis, hemolysis, and an infusion syndrome. Phenytoin may cause significant peripheral vascular side effects, all of which can be avoided with fPHT.

Adverse events with the use of lacosamide have been reported. Non-life-threatening adverse events of chorea (n=1) and oculogyric crisis (n=1) were reported in the aforementioned case series.¹⁰⁰ Neurotoxicity consisting of mostly dizziness, imbalance, diplopia, and sedation has also been reported with the use of lacosamide.¹⁰⁴ Because this adverse event has been reported only in patients taking lacosamide as a maintenance medication in conjunction with a voltage-gated sodium channel-blocking anticonvulsant, neurotoxicity would not be expected from the use of lacosamide in SE.

Established GCSE: summary of treatment options

Although a hydantoin has historically been used as the first-line agent in established GCSE, there is little evidence to support it as effective as PB. While numerous studies have validated the effectiveness of PB, its adverse effect profile relegating it to a second-line agent in the minds of many practitioners. Clearly, VPA, levetiracetam, and lacosamide have better safety profiles than either PHT/fPHT or PB. Because most studies evaluating VPA, levetiracetam, or lacosamide were underpowered, they enable only cautious interpretation that is not accompanied by evidenced-based decisions. The established SE trial 2013 is currently being conducted among patients older than 2 years of age.¹⁰⁵ This study will compare fPHT, levetiracetam, and VPA. Regardless of which agent is used, Olsen et al⁷⁶ noted that only 5% of patients treated within 3 hours required anesthesia compared to 38% treated 3 to 24 hours and 60% treated after 24 hours. Limdi et al⁷⁴ and Agarwal et al⁷⁵ also noted that time to treat affected outcome.

Refractory GCSE

The definition of refractory GCSE is based on the number of anticonvulsants used. A patient is considered to have refractory SE when seizures continue despite first- and second-line treatments,^{5,8,21,22,72} seizure duration is greater than 1 hour,^{7,8,27,72} or there is a need for general anesthesia (Table 1).

The variability in definitions makes it difficult to estimate the incidence, but studies suggest that refractory GCSE occurs in 9% to 44% of patients with GCSE.^{106,107} Prolonged seizures cause severe neurological sequelae^{108,109} and/or death.¹¹⁰⁻¹¹³ Sahin et al¹⁰⁹ studied morbidity in normal healthy individuals with acute refractory generalized seizures and found that none returned to baseline neurological status and all developed intractable epilepsy. Mortality also may be high, ranging from 16% to 77%.¹¹⁰⁻¹¹³ In a meta-analysis of 111 children with refractory GCSE, the overall mortality was 20% in symptomatic cases and 4% in idiopathic cases.¹¹¹

There is a lack of consensus regarding the optimal therapeutic approach, but patients who continue to be unresponsive are treated with continuous infusion of barbiturate (i.e., PTB, thiopental), BDZ (i.e., DZP, LZP, MDL), or PRO. Thiopental has not been available for many years, and there is currently no manufacturer of this product in the United States. The effectiveness of these agents is such that Fountain and Fugate¹⁴¹ suggested that practitioners should skip second-line therapy to avoid major time delays and move immediately to anesthesia with IV MDL in those failing initial BDZ therapy.

Unfortunately there are no randomized, controlled trials comparing these agents. Surveys conducted in the United States¹¹⁵ and Europe¹¹⁶ almost a decade ago noted that barbiturates are the most popular agent in refractory GCSE, followed by PRO and MDL. More recent consensus protocols/guidelines suggest that thiopental or PRO,³¹ PTB or PRO,²⁶ or PRO, PTB, or MDL^{2,21,25} are preferred. Capovilla et al² noted that the selection of 1 agent over another should depend on the patient's general condition and the agent's benefits versus risk of adverse effects. Use of an agent is also driven by the availability of medical staff with expertise in general anesthesia.² Claassen et al¹¹⁷ evaluated 28 retrospective trials that used barbiturates, MDL, or PRO in 193 adult patients with refractory GCSE. The authors concluded that PTB was more effective than PRO or MDL in preventing seizure recurrence, but it was associated with more adverse effects.

Pentobarbital

Barbiturates such as PTB, PB, and thiopental have been used for decades to induce general anesthesia in pediatric patients with refractory

GCSE.^{113,118-124} Although PB has been used,^{125,126} PTB is preferred for general anesthesia because its rapid penetration into the brain results in a quicker onset of antiepileptic activity. It has a shorter half-life in serum than PB, but both agents distribute into fat causing prolonged elimination after continued use. Pentobarbital is highly effective in terminating seizures in 74% to 100% of patients with refractory GCSE.^{111,113,123,124}

Most reports describing the use of PTB involve case reports^{118-120,122} or retrospective reviews.^{113,124} Kim et al¹¹³ reviewed the use of PTB in 23 children with refractory GCSE. Patients received a small loading dose (5 mg/kg) followed by 1 to 3 mg/kg/hr for at least 48 hours. The dose was adjusted based on clinical seizures and EEG findings. Among the 23 patients reviewed, 12 were controlled, 6 were unresponsive, and 5 relapsed after discontinuation or during tapering. The mortality rate among the relapsed and nonresponder groups combined was 90.9%, but no deaths occurred among the responder group ($p < 0.001$).

Barberio et al¹²⁴ evaluated the use of PTB in 30 pediatric patients given a mean loading dose of 5.4 ± 2.8 mg/kg and an initial infusion of 1.1 ± 0.4 mg/kg/hr (maximum: 4.8 ± 2 mg/kg/hr). Thirty-three percent of patients achieved a sustained burst suppression pattern on EEG without relapse. Another 66.7% experienced relapse, but 60% of those eventually re-achieved burst suppression. Children achieving burst suppression within 24 hours of PTB initiation and those older than 5 years of age were 1.5 times more likely to have a positive outcome.

Pentobarbital should be given as a loading dose of 10-20 mg/kg over 1 hour, followed by a maintenance infusion of 1 to 5 mg/kg/hr (Table 2). Most patients achieve burst suppression at a dose of 1 mg/kg/hr,¹²⁴ but the dose should be increased every 2 minutes by 1 mg/kg/hr until the desired effect is achieved.² Subsequent administration of an additional dose of 5 mg/kg (combined with EEG monitoring) may allow for more rapid titration of dose to the therapeutic goal.

Pentobarbital duration of therapy remains controversial, as the endpoint for success continues to be debated. After a period of control, a loss of EEG burst suppression may suggest the development of pharmacologic tolerance, which may require a dosage increase. Seizures during

withdrawal are not only frustrating and time-consuming but also predict a worsened outcome. Seizures tend to occur if the infusion is abruptly discontinued; hence, tapering the dose is recommended. Most practitioners recommend tapering PTB when burst suppression has been achieved for 12 hours^{119,122} or 24 hours.¹²⁷ However, others argue that longer periods (24-48 hours) are associated with lower rates of recurrent seizures.¹²⁸⁻¹³⁰ Still others suggest a criterion of 3 to 9 bursts/min¹³¹ or advocate dividing burst duration by suppression duration to determine the burst suppression-to-duration ratio. Patients who received prolonged therapy and those taking PB at the time of withdrawal may be less likely to relapse.¹²⁸ If seizures reoccur during tapering, the last successful dose should be reinstated. Once seizure control is regained, the medication should be tapered at a slower rate than what was previously used.

Continuous infusion of anesthetic agents usually requires mechanical ventilation and immobilization, which may lead to a multitude of complications including infections and thromboembolism. Large doses of PTB may be associated with myocardial depression and low cardiac output. Barbiturate-induced hypotension is a frequent complication but rarely requires discontinuation of therapy. When it does occur, the rate of infusion should be decreased, fluids should be increased, or a vasopressor should be given.¹²⁴ Patients who do not develop hypotension requiring vasopressors have better survival rates.¹²⁰ Pulmonary edema, skin edema, and ileus have also been described when the duration of PTB therapy exceeds 4 days.¹¹⁸

Pentobarbital may cause white blood cell dysfunction that contributes to an increased rate of nosocomial infections, especially pneumonia. Barbiturates may induce hepatic isoenzymes, which may cause drug-drug interactions. It may take days for a patient to regain full consciousness following discontinuation of PTB. In fact, Lowenstein et al¹¹⁹ reported that spontaneous eye opening and respirations in a 14-year-old occurred after 36 hours and 3 days, respectively.¹¹⁹

Propylene glycol (1,2-propanediol) is the pharmaceutical solvent used to formulate parenteral LZP, DZP, and PTB. Although large doses of propylene glycol have been associated with toxicity, the incidence is unknown. Acute kidney injury, hyperosmolality, and lac-

tic acidosis that presents as a high-anion gap metabolic acidosis and osmolar gap has been reported.¹³²⁻¹³⁴ In critically ill patients receiving agents containing propylene glycol, an osmolar gap greater than 10 was reported to cause toxicity.¹³⁵ Although most patients respond to discontinuation of agents containing propylene glycol accompanied by hemodynamic support, those with multiorgan failure may require fomepizole or hemodialysis.^{136,137}

Midazolam

Midazolam is an injectable BDZ that is fast acting, rapidly penetrates the blood-brain barrier, and exerts a short duration of action. Studies suggest efficacy in 71% to 97% of patients.¹³⁸⁻¹⁴⁵ A meta-analysis of 111 children indicated that MDL was as effective as other coma-inducing medications.¹¹¹ Important in the discussion of efficacy is the target goal for success. Most studies used termination of seizures on EEG as the endpoint for success. EEG burst suppression is rarely achieved with the recommended doses of MDL, and some suggest that it should not be the goal for success.²⁶

Although different dosing regimens have been used, many suggest that an initial bolus dose of 0.1-0.5 mg/kg, followed by an infusion of 0.05-2 mg/kg/hr will control refractory GCSE in most children (Table 2).¹³⁸⁻¹⁴⁵ Doses as large as 24 mcg/kg/min have been required.¹⁴⁰

Very rapid control of seizures has been reported, occurring in 0.3-1.1 hours.¹³⁸⁻¹⁴⁴ Some^{138,139,143} but not all^{144,145} of the studies noted a longer time to control seizures when smaller loading doses were used. If a patient is not controlled, the dose should be increased every 15 minutes by 1-2 mcg/kg/min (0.06-0.12 mg/kg/hr).^{2,140} If clinical seizures persist 5 minutes after the initial MDL bolus, then administer an additional 0.2 mg/kg while continuing the infusion. If clinical seizures continue after another 5 minutes, then administer another MDL bolus of 0.2 mg/kg and increase the infusion to 0.2 mg/kg/hr. If seizures persist at the maximum MDL infusion rates (generally, 2 mg/kg/hr) or the infusion is not tolerated, another agent should be considered.

Tachyphylaxis rapidly develops within 24 to 48 hours; hence, the dose is often increased to prevent seizure relapse.¹⁴⁶ After initial control, seizures have been observed in 47% to 57% of patients,^{142,144} and generalized convulsive seizures

recurred in 6% to 19%.¹⁴²⁻¹⁴⁴ This may require an increase in dosage or a change in therapy. Ferlisi and Shorvon¹⁴⁷ reported seizure control was achieved with a change in dose in 12%, 7%, and 6% of those given PRO, MDL, and barbiturates, respectively. Seizures occurred even when MDL infusion rates were 1.44 mg/kg/hr. Recurrent seizures that required a change in therapy occurred most frequently with MDL (3%) compared to PRO (1.3%) and barbiturates (0%).¹⁴⁷ Withdrawal seizures that occurred within 48 hours of discontinuation of MDL have been reported less frequently in those receiving large doses.¹⁴⁸ If withdrawal seizures occur, the anticonvulsant should be reintroduced at the dosage that previously achieved seizure control.

The optimal length and tapering of any anesthetic treatment has not been addressed in prospective studies, and retrospective observations do not clearly favor any specific protocol. Wilkes and Tasker¹⁴⁹ recommended a seizure-free period of 24 to 48 hours before undertaking a trial of weaning from the MDL infusion. When tapering, the rate should be decreased by 1 to 2 mcg/kg/min every 15 minutes.¹⁴⁰

Many studies report no adverse effects with MDL.^{138,140,141,143} A few reports have described hypotension requiring IV fluids or vasopressor support,^{142,150} whereas others describe cardiovascular stability even in children receiving large doses (24 mcg/kg/min¹⁴⁰ or 32 mcg/kg/min¹⁴²). Hypotension occurred more frequently with PTB compared to MDL and PRO (77% vs. 34%).¹¹⁷ Endotracheal intubation and mechanical ventilation was required less frequently with MDL. Due to MDL's short half-life, waking after discontinuation should not be excessively prolonged; however, MDL does accumulate with continued use, which can result in a longer terminal half-life.¹⁵¹ Rivera et al¹³⁸ reported that patients were completely awake within a mean of 4 hours (range, 2-8.5 hours) after the MDL infusion was discontinued. When adverse effects do occur, the patient's recovery is quick. In addition, the availability of a pharmacological antidote for BDZs, flumazenil, lends to the safety of MDL.

Propofol

Propofol is an IV alkyl-phenol general anesthetic unrelated to BDZ and barbiturates. It has a short half-life that allows for easy titration and withdrawal and rapid awakening after drug

cessation. Although it does accumulate with prolonged administration, the consequences are not as significant as that seen with MDL and PTB. Like other anesthetics, there are few studies of its efficacy in refractory GCSE¹⁵²⁻¹⁵⁵ and little information that helps to clarify its use relative to other therapies. It is effective in quickly terminating refractory GCSE, but it is no more effective than barbiturates.¹⁵⁴⁻¹⁵⁷

Propofol increases the potency of GABA-ergic inhibitory neurotransmission (Figure). At concentrations that are clinically achieved, it reversibly but non-competitively inhibits cellular excitation at the NMDA glutamate receptor to reduce the probability of channel opening. It is also thought that propofol stimulates the production and release of nitric oxide and at high concentrations protects against the toxicity of NMDA and glutamate. It does not affect kainic acid or AMPA.

Although several studies have compared PRO to barbiturates, most studies were underpowered. Propofol induces burst suppression within 35 minutes of initiation, but maintenance of burst suppression may require frequent dosage titration.¹⁵⁵ Once EEG burst suppression has been achieved, the dose should be reduced.

Propofol is given as a loading dose of 1-2 mg/kg that can be repeated every 3 to 5 minutes until clinical response is achieved, up to a maximum of 10 mg/kg (Table 2). This is followed by a continuous infusion (1-4 mg/kg/hr).³¹ Although much larger doses have been reported (10-15 mg/kg/hr),²¹ prolonged infusions >4 mg/kg/hr have been associated with PRO-related infusion syndrome (PRIS) in critically ill adults and pediatric patients receiving continuous infusion PRO for anesthesia or sedation.¹⁵⁸ Signs and symptoms of PRIS include progressive metabolic acidosis, hemodynamic instability, and bradyarrhythmia that are refractory to aggressive pharmacological treatments. It may occur with or without the presence of hepatomegaly, rhabdomyolysis, or lipemia.

Vital signs, especially blood pressure for hypotension, should be carefully monitored. Continuous ECG should assess for dysrhythmias, including bradycardia, ventricular tachycardia or fibrillation, right bundle branch block, and a widened QRS complex. Although no guidelines have been proposed for laboratory monitoring in patients receiving PRO, it would seem prudent to assess serum lactic acid, serum triglycerides,

serum creatinine, CK, and hepatic enzymes in anyone given the drug in doses larger than 4 mg/kg/hr and/or those receiving an infusion for longer than 48 hours.

Cardiotoxicities should be managed with aggressive pharmacological therapies and cardiac pacing. Practitioners have successfully managed PRIS with venovenous hemodiafiltration,¹⁵⁹⁻¹⁶¹ charcoal hemofiltration,¹⁶² or extracorporeal membrane oxygenation.¹⁶³⁻¹⁶⁵ However, plasmapheresis does not seem beneficial.¹⁶⁰ A retrospective case series of 41 patients with refractory GCSE noted that 10% of patients had sudden unexplained cardiorespiratory arrests (2 fatalities) and 35% had non-life-threatening features of PRIS.¹⁶⁶ Fatalities were also reported when PRO was administered in conjunction with a ketogenic diet.¹⁶⁷

Propofol has also been reported to be proconvulsant in some patients.^{168,169} It may also cause involuntary movements having a myoclonic appearance that resolve following withdrawal of PRO.¹⁷⁰ Differentiation from seizures may be challenging even with EEG monitoring, as the events may be obscured by movement artifacts.

Ketamine

Prolonged SE results in an increase in NMDA receptors. Stimulation of these receptors by glutamate may promote seizure activity. For this reason, NMDA-receptor antagonists such as ketamine have been investigated (Figure). A summary of the findings from more than 40 preclinical studies can be found in a recently published review paper.¹⁷¹ Ketamine can be used to successfully treat soman-induced prolonged SE within 1 hour of intoxication, reduce neuroinflammation, and change brain metabolism. In this review, it was also noted that seizures lasting more than 1 hour were not successfully treated with ketamine alone.¹⁷¹

There are several case reports and retrospective studies describing the use of IV ketamine for refractory GCSE in pediatric patients (Table 6).¹⁷²⁻¹⁷⁴ A 13-year-old patient with SE refractory to PB, PHT, continuous MDL, PRO, IV VPA, IV lidocaine, and PTB coma was treated with a loading dose of 2 mcg/kg ketamine, which provided clinical and electrographic control within 90 seconds. The patient's seizures ceased for 15 minutes and were subsequently controlled by using a continuous infusion of ketamine (maximum rate: 7.5

Table 6. Use of Ketamine for Refractory Status Epilepticus in Pediatric Patients

Reference	Study Type (n)	Age	Loading Dose	Continuous Infusion Dose	Seizure Cessation	ADRs
Gaspard ¹⁷⁴	Retrospective, multicenter (n=60; 12 pediatrics)	7 mo to 74 yr	1.5 mg/kg (median); 5 mg/kg (maximum)	2.75 mg/kg/hr (median); 10 mg/kg/hr (maximum)	32% response rate	PRIS-like (n=1); SVT (n=2); AF (n=1)
Rosati ¹⁷³	Open-label case series (n=9)	16 mo to 10 yr	2-3 mg/kg twice	10 mcg/kg/min; 60 mcg/kg/min (maximum)	67% response rate	None observed
Sheth and Gidal ¹⁷²	Case report	13 yr	2 mcg/kg	7.5 mcg/kg/hr	Within 90 sec of bolus	None observed

ADR, adverse drug reaction; AF, atrial fibrillation; PRIS, propofol-related infusion syndrome; SVT, supraventricular tachycardia

mcg/kg/hr).¹⁷² A retrospective review found that 6 of 9 pediatric patients (16 months to 10 years of age) had both clinical and electrical resolution following a median dose of 40 mcg/kg/min.¹⁷³ The only adverse events reported were increased saliva production (n=9) and mild increase in liver enzymes with concomitant PB (n=4). A multicenter, retrospective study evaluated the use of IV ketamine in 60 episodes of refractory GCSE in 46 adult and 12 pediatric patients.¹⁷⁴ A loading dose (median 1.5 mg/kg; maximum 5 mg/kg) and a subsequent continuous infusion (median 2.75 mg/kg/hr; maximum 10 mg/kg/hr) controlled seizures in 19 episodes (32%). Adverse events included a syndrome similar to PRIS (n=1), supraventricular tachycardia (n=2), and atrial fibrillation (n=1).

An advantage of ketamine is its ability to maintain arterial blood pressure, pulse rate, and cardiac output.¹⁷⁵ It may cause hallucinations upon awakening, increased salivation, and increased intraocular and intracranial pressures. Although neurotoxicity has rarely been reported in infants or children, it has not been reported in any pediatric cases of SE. Finally, ketamine has been reported to be proconvulsant in some patients. In summary, ketamine is a reasonable agent to consider in refractory GCSE for which general anesthesia has failed, especially in those with cardiac instability.

Inhaled anesthetics

Isoflurane produces a dose-related reduction in cortical electrical activity, decreases cerebral metabolic rate and oxygen consumption, and does not increase cerebral blood flow. Although

the mechanism of its anticonvulsant effects is not fully elucidated, it may be attributable to the potentiation of inhibitory postsynaptic GABA_A receptors. Today, inhaled anesthetics are not used until other approaches fail, and only a few studies have used inhaled anesthetics (particularly isoflurane) for the treatment of refractory SE.¹⁷⁶⁻¹⁷⁸

Although concentrations required to maintain burst suppression are variable, isoflurane generally stops seizure at concentrations of 0.5% to 3%, which are not ordinarily associated with hemodynamic effects. Major limitations to the use of inhaled anesthetic involves logistical difficulties in using this in the intensive care unit, adverse effects, and the high rate of seizure recurrence after discontinuation of the therapy. Isoflurane can induce hypotension, so close hemodynamic monitoring is necessary, with administration of isotonic fluids and vasopressors as needed. Long-term use may cause atelectasis, infections, paralytic ileus, and deep venous thrombosis.¹⁷⁷ Fugate et al¹⁷⁸ also raised concerns about isoflurane and central nervous system toxicity, especially in thalamic and cerebellar regions.

Magnesium

Intravenous magnesium sulfate has been used primarily for seizures associated with eclampsia. Although magnesium has antiseizure properties, the mechanism by which it produces this effect is unknown. It has been shown to influence several receptors and ion channels. It is thought to work with divalent cations (e.g., Ca⁺⁺) to maintain electrical stability of the neuronal membrane (Figure). That said, magnesium and calcium have opposing effects on synaptic release of neuro-

transmitters. Calcium facilitates synaptic release whereas magnesium inhibits release; hence, blockage can be excitatory or inhibitory based on the nature of the synapse. Although magnesium causes voltage-dependent blockade of NMDA-induced currents, this effect tends to disappear at depolarized levels of the membrane potential. Therefore, it is not certain that magnesium blocks NMDA channels. Because it has no significant toxicity, it seems reasonable to give it in all cases of super-refractory SE, even in the presence of a normal serum magnesium value.¹⁴⁷ One regimen suggested administering an initial loading dose and continuous infusion sufficient to increase the serum level above 7 mEq/L.¹⁷⁹

Super-refractory GCSE

Super-refractory GCSE involves seizures that have persisted or recurred for 24 hours or more after the administration of anesthesia (Table 1). This includes exacerbations that occur when reducing the dose of an anticonvulsant or withdrawing anesthesia. To date, no randomized trials have evaluated treatment options for super-refractory GCSE; hence, the basis of information is generally derived from case reports. Other anticonvulsants (e.g., topiramate), immunomodulatory compounds (steroids, IVIG), and non-pharmacological approaches (hypothermia, electroconvulsive treatment, vagus nerve stimulation, and the ketogenic diet) have been used in cases of protracted, super-refractory GCSE. Surgical intervention is rarely an option. There are no clear guidelines about dose or duration of therapy and often little to no evaluation of effectiveness.

Topiramate

Topiramate influences a variety of receptors and ion channels. Similar to the barbiturates and hydantoins, topiramate exhibits voltage-sensitive sodium-channel blockade. It also potentiates GABA activity at some subtype of the GABA_A receptor (Figure) to significantly increase brain concentrations of GABA. This effect occurs independent of the BDZ site on the GABA_A receptor; hence, topiramate may be effective in patients who display pharmacoresistance to BDZ. Topiramate also antagonizes excitatory glutamatergic transmission at the AMPA/kainite subtype of the glutamate receptor, which may be its most influential mechanism in termination of electrical discharges in patients with refractory epilepsy.

Although topiramate inhibits high-voltage-activated T-type calcium channels this action does not significantly contribute to its effectiveness as an anticonvulsant.

Several reports in pediatric patients have described the successful use of rapidly titrated, nasogastrically administered topiramate (Table 7).¹⁸⁰⁻¹⁸⁴ These reports have included 1 prospective, observational study (n=14 patients) and 4 case series/reports (n=9 patients). Patients ranged from 2 months to 16 years of age, and 10 experienced new onset seizures. Doses ranged from 2 to 25 mg/kg/day. Time to response was from 2 hours to 6 days.

Topiramate should be implemented at full therapeutic doses (5-10 mg/kg/day) divided 3 times a day. To administer nasogastrically, the topiramate tablets should be crushed to a powder, mixed with water, and administered by syringe into the nasogastric tube. Once seizures are controlled, the topiramate dose should be tapered to a normal age/weight-appropriate maintenance dosage.

A concern with the aggressive implementation of large doses is possible hyperchloremic, non-anion gap, metabolic acidosis due to inhibition of type II and IV carbonic anhydrase enzymes.¹⁸⁵ Contributing factors are not fully understood, but metabolic acidosis does occur more frequently in children. Dose does not appear to be the sole determinate as it has been noted at doses as small as 50 mg/day^{185,186} and following overdoses.^{187,188} If metabolic acidosis occurs it generally responds to discontinuation of topiramate; however, it can be treated with orally administered citrates with the goal of maintaining a serum bicarbonate concentration of at least 20 mEq/L.

Immunomodulatory compounds

Immunomodulating therapies (i.e., corticosteroids, IV immune globulin, and plasmapheresis) have been given in cases of super-refractory GCSE.^{189,190} Their use is predicated upon recent discoveries that super-refractory GCSE may be due to antibodies directed against the voltage-gated potassium channels and the NMDA receptor. There is increasing evidence that inflammation plays an important role in epileptogenesis, especially the activation of specific inflammatory signaling pathways, such as the interleukin-1 receptor/Toll-like receptor (IL-1R/TLR) pathway.¹⁸⁹ There is also the possibility that other undiscovered

Table 7. Use of Topiramate for Refractory Status Epilepticus in Pediatric Patient

Reference	Study Type (n)	Age	No. of AEDs Prior to TPM	TPM Route	TPM Dosage	Time to TPM Response	ADRs
Kahriman ¹⁸⁰	Case series (n=3)	4.5 mo to 11 yr	2-6	NG	2-3 mg/kg/day (5-6 mg/kg/day maximum)	Within 24 hr	*
Blumkin ¹⁸¹	Case series (n=2)	5 mo to 32 mo	3-7	NG	2-5 mg/kg, then 22-25 mg/kg/day; maintenance 10 mg/kg/day	6 days	Anorexia (n=1)
Perry ¹⁸³	Case series (n=3)	2 mo to 6 yr	2	PO or enteral	10 mg/kg/day for 2 days, then 5 mg/kg/day	12-21 hr	*
Bragatti ¹⁸⁴	Case report (n=1)	16 yr	1	*	2.5 mg/kg/day	8 hr	*
Akyildiz ¹⁸²	Prospective observational (n=14)	6 mo to 12 yr	0-2	NG	5 mg/kg loading dose then 5 mg/kg/day divided twice daily (25 mg/kg/day maximum)	Median, 5.5 hr (range 2-48 hr)	Mild metabolic acidosis (n=3)

ADRs, adverse drug reactions; AEDs, antiepileptic drugs; NG, nasogastric; PO, by mouth; TPM, topiramate

*Not mentioned in the report or unknown.

antibodies may contribute to the pathogenesis of super-refractory GCSE. Steroids may also decrease intracranial pressure, reverse blood-brain barrier opening, and reverse GABAergic inhibition, which may influence persistent seizures.

There is little evidence to support the use of steroids; however, unless there are specific contraindications, a trial of large doses of steroids should be given to all patients with an unidentified cause of super-refractory GCSE. Although prednisolone is no longer available in the United States, Shorvon and Ferlisi¹⁸⁹ recommend prednisolone, 1 g/day IV, for 3 days, followed by 0.25 mg/kg/day four times daily.¹⁸⁹ If there is a response, treatment is continued with long-term steroids, IVIG, and later, other immunomodulatory agents such as cyclophosphamide or rituximab.¹⁸⁹ Neuroactive steroids (e.g., allopregnanolone) are also being explored.¹⁹¹

If there is no response this should be followed by 1 or 2 courses of IVIG, 0.4 g/kg/day for 5 days.¹⁸⁹ This is especially true if inflammatory processes such as Rasmussen's encephalitis or new onset refractory SE are suspected.^{192,193}

Although plasma exchange is rarely used, it has been tried.¹⁸⁹ If plasmapheresis is used, it may reduce serum concentrations of an anticonvulsant; therefore, therapeutic drug monitoring is critical to the maintenance of serum concentrations as supplemental antiepileptic dosing may be required. This is especially true for those agents that are not highly protein bound.

Hypothermia

Animal studies show that controlled, moderate hypothermia reduces excitatory transmission and epileptic discharges, reduces brain edema by altering permeability of the blood-brain barrier and pro-inflammatory reactions, and has neuroprotective effects (decreases apoptosis). It also decreases cerebral metabolic rate, oxygen use, and ATP consumption.^{189,194}

Few data have assessed the efficacy or safety of hypothermia in refractory GCSE. One case series described 3 children with refractory SE who were successfully treated with hypothermia (30°C-31°C) and barbiturate coma for 48 to 120 hours. The effects of hypothermia could not be separated from those of barbiturate.¹⁹⁵ Corry et al¹⁹⁶ reported a series of 4 patients who successfully gained seizure control after receiving therapeutic hypothermia (31°C-35°C) for 20 to 61 hours

using endovascular cooling. Mild hypothermia (31°C–36°C) together with MDL, ketamine, or thiopental for 1 to several days has been reported to control refractory SE, but seizures can recur after rewarming. Rossetti¹⁹⁷ recommended that only mild hypothermia (32°C–35°C) be given for 24 to 48 hours as a trial; however, it should not be used in combination with barbiturate anesthetics.

Adverse effects include acid–base and electrolyte disturbances, disseminated intravascular coagulation, coagulation disorders, thrombosis, infection, cardiac arrhythmia, bowel ischemia, and paralytic ileus.¹⁹⁶ Cardiovascular and coagulation parameters, biochemistry and acid-base balance, and serum lactate should be monitored. Hypothermia may significantly reduce the clearance of several drugs, including anesthetics and anti-epileptics, resulting in the need for monitoring of serum concentrations. Reduced drug clearance is attributed to decreased activity of the cytochrome P450 enzyme system, reduced cardiac output, and decreased glomerular filtration rate.^{198,199}

Electroconvulsive therapy

Electroconvulsive therapy (ECT) is listed as an indication for refractory SE by the American Psychiatric Association Task Force and has been used mostly in cases of refractory nonconvulsive SE.²⁰⁰ Its mechanism of action is unknown, but some evidence suggests that it enhances pre-synaptic transmission of GABA and prolongs the refractory period following a seizure.^{189,201} Lambrecq et al²⁰² reviewed available information on the use of ECT in refractory SE. They noted cessation of SE in 80% of cases and complete recovery in 27% of patients. It remains unclear whether ECT or subdural electrode stimulation will terminate refractory GCSE; however, it is an option when established treatments including anesthesia have failed to abort the most severe cases of refractory GCSE.

Ketogenic diet

There have been case reports,²⁰³ case series,^{204,205} and retrospective reviews^{206,207} of the successful use of ketogenic diet in patients with refractory SE. The reports convincingly show that the diet should probably be tried in all severe cases of super-refractory SE.

Nabbout et al²⁰⁵ reported the successful use of a fat-to-combined protein and carbohydrate ratio of 4:1 in 9 cases of super-refractory SE caused by

febrile illness.²⁰⁵ Efficacy occurred in 7 patients within 2 to 4 days of the onset of ketonuria, which occurred 4 to 6 days after implementing the diet. One patient experienced relapsed intractable SE and died following early disruption of the diet. Nam et al²⁰⁶ retrospectively reviewed the medical records of 4 children and 1 adult with refractory SE presumed to be due to viral encephalitis.²⁰⁶ The overall seizure frequency decreased to <50% of baseline in a median of 8 days. At 1 month, 2 patients were seizure-free, 1 patient showed seizure reduction of >90%, and the other 2 patients had >75% decrease without generalized seizures.

In a retrospective review of data from 4 centers, Thakur et al²⁰⁷ described successful resolution of SE in 90% of critically ill adult patients (n=10) with super-refractory SE who undertook the diet. The median duration of SE and the median number of anticonvulsants used before initiating the ketogenic diet was 21.5 days and 7 drugs, respectively. Ninety percent of patients achieved ketosis, and SE ceased in all patients achieving ketosis in a median of 3 days. Cobo et al²⁰⁴ reported the use of the ketogenic diet in 4 critically ill children (9 weeks to 13.5 years of age) with refractory SE. Although delayed ketosis and persistently elevated glucose measurements posed challenges in implementation, patients were weaned from continuous infusions of anesthetics without recurrence of SE. None of the patients experienced complete seizure cessation.

Wheless¹⁹⁰ suggested that the patient be screened for metabolic disorders as a possible cause of the refractory SE before initiating the diet. Children in the intensive care unit are often receiving multiple medications, requiring consultation with the pharmacist to switch to formulations with no or minimal carbohydrate content. Close monitoring of total daily fluid, ketosis, and potential complications is essential. If metabolic acidosis develops, treatment is suggested to maintain serum bicarbonate concentrations of >18 to 20 mEq/L. PRIS was reported in a 10-year-old patient with refractory SE who received the ketogenic diet along with PRO.¹⁶⁷ The authors speculated that the 2 agents impaired fatty-acid oxidation and recommended that they not be used simultaneously.¹⁶⁷

Vagus nerve stimulation

Although acute vagus nerve stimulation (VNS) has been suggested as an effective therapy in

patients with super-refractory GCSE, it has been used in few children²⁰⁸ and adults.^{209,210} After 2 weeks of aggressive medical treatment, placement of VNS resulted in immediate cessation of seizures in a 13-year-old patient with refractory SE.²⁰⁸ A recent publication describing 153 pediatric patients treated with VNS reported complete seizure remission in approximately 5%.²¹¹ However, other pediatric case series have reported a reduced seizure frequency in as many as 68% of patients.²¹²

CONCLUSIONS

GCSE is one of the most common neurologic emergencies and can be associated with significant morbidity and mortality if not treated promptly and aggressively. Management is staged and generally involves the use of life support measures, identification, and management of underlying causes, and rapid initiation of antiepileptic medications. In a non-hospital setting, PR DZP is being replaced by IN MDL or IM LZP. Impending GCSE is best managed by IV LZP in the emergency department, but intranasal MDL is being used increasingly. Although a hydantoin has historically been used as the first-line anticonvulsant in patients unresponsive to a BDZ, there is little evidence to support that it is as effective as PB. There is a lack of consensus regarding the optimal therapeutic approach for refractory GCSE, but continuous infusion of barbiturates (PTB, thiopental), BDZs (LZP, MDL), or PRO may be used. Super-refractory GCSE has been successfully treated with other anticonvulsants (e.g., topiramate), immunomodulatory compounds (steroids, IVIG), and non-pharmacological approaches (hypothermia, electroconvulsive treatment, vagus nerve stimulation, and ketogenic diet), but there are no studies or clear guidelines to drive therapeutic decisions.

Disclosures Dr. Wheless is a consultant and/or member of the speaker's bureau for Cyberonics, Eisai, Lundbeck, Pfizer, Questcor, Sunovion, Supernus, and Upsher-Smith and has received grants from Cyberonics, Eisai, GSK, Novartis, and Upsher-Smith. Drs. Alford and Phelps declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria.

Abbreviations BDZ, benzodiazepine; DZP, diazepam; EEG, electroencephalogram; fPHT, fosphenytoin; GCSE, gen-

eralized convulsive status epilepticus; IM, intramuscular; IV, intravenous; LZP, lorazepam; MDL, midazolam; NMDA, N-methyl-D-aspartate; PB, phenobarbital; PHT, phenytoin; PR, rectal; PRO, propofol; PRIS, propofol-related infusion syndrome; PTB, pentobarbital; SE, status epilepticus; VPA, valproate

Correspondence Stephanie J. Phelps, BSPharm, PharmD, University of Tennessee Health Science Center, College of Pharmacy, 881 Madison Avenue, Room 244, Memphis, TN 38163, email: sphelps@uthsc.edu

REFERENCES

- Huff JS, Morris DL, Kothari RU, Gibbs MA. Emergency department management of patients with seizures: a multicenter study. *Acad Emerg Med*. 2001;8(6):622-628.
- Capovilla G, Beccaria F, Beghi E, et al. Treatment of convulsive status epilepticus in childhood: Recommendations of the Italian League Against Epilepsy. *Epilepsia*. 2013;54(suppl 7):23-34.
- DeLorenzo RJ, Garnett LK, Towne AR, et al. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. *Epilepsia*. 1999;40(2):164-169.
- Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. *Epilepsia*. 2006;47(9):1499-1503.
- Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. *Epilepsia*. 1999;40(1):120-122.
- Shinnar S, Berg AT, Moshe SL, Shinnar R. How long do new-onset seizures in children last? *Ann Neurol*. 2001;49(5):659-664.
- Wasterlain CG, Chen JW. Definition and classification of status epilepticus. In: Wasterlain CG, Treiman DM, eds. *Status Epilepticus*. Cambridge, MA: MIT Press; 2006:11-16.
- Lothman E. The biochemical basis and pathophysiology of status epilepticus. *Neurology*. 1990;40(5(suppl 2)):13-23.
- DeLorenzo RJ, Towne AR, Pellock JM, Ko D. Status epilepticus in children, adults, and the elderly. *Epilepsia*. 1992;33(suppl 4):S15-S25.
- Singh RK, Gaillard WD. Status epilepticus in children. *Curr Neurol Neurosci Rep*. 2009;9(2):137-144.

11. Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. *Brain Res.* 1998;814(1-2):179-185.
12. Chen JW, Naylor DE, Wasterlain CG. Advances in the pathophysiology of status epilepticus. *Acta Neurol Scand.* 2007;186:7-15.
13. Naylor DE. Glutamate and gaba in the balance: convergent pathways sustain seizures during status epilepticus. *Epilepsia.* 2010;51(suppl 3):106-109.
14. Goodkin HR, Joshi S, Kozhemyakin M, Kapur J. Impact of receptor changes on treatment of status epilepticus. *Epilepsia.* 2007;48(suppl 8):14-15.
15. Goodkin HP, Sun C, Yeh JL, et al. Gaba(a) receptor internalization during seizures. *Epilepsia.* 2007;48(suppl 5):109-113.
16. Wasterlain CG, Chen JW. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. *Epilepsia.* 2008;49(suppl 9):63-73.
17. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. *Pharmacol Ther.* 2001;90(1):21-34.
18. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. *Lancet Neurol.* 2006;5(3):246-256.
19. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. *Nat Med.* 2004;10(7):685-692.
20. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. *Neurotherapeutics.* 2007;4(1):18-61.
21. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. *Neurocrit Care.* 2012;17(1):3-23.
22. Treatment of convulsive status epilepticus. Recommendations of the epilepsy foundation of america's working group on status epilepticus. *JAMA.* 1993;270(7):854-859.
23. Appleton R, Choonara I, Martland T, et al. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, members of the Status Epilepticus Working Party. *Arch Dis Child.* 2000;83(5):415-419.
24. Wheless JW, Clarke DE, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. *Epileptic Disord.* 2007;9(4):353-412.
25. Shorvon S, Baulac M, Cross H, et al. The drug treatment of status epilepticus in europe: Consensus document from a workshop at the First London Colloquium on Status Epilepticus. *Epilepsia.* 2008;49(7):1277-1285.
26. Meierkord H, Boon P, Engelsens B, et al. EFNS guideline on the management of status epilepticus in adults. *Eur J Neurol.* 2010;17(3):348-355.
27. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. *N Engl J Med.* 2001;345(9):631-637.
28. Leppik IE, Derivan AT, Homan RW, et al. Double-blind study of lorazepam and diazepam in status epilepticus. *JAMA.* 1983;249(11):1452-1454.
29. Cock HR, Schapira AH. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. *QJM.* 2002;95(4):225-231.
30. Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. *Cochrane Database Syst Rev.* 2008(3):Cd001905.
31. Minicucci F, Muscas G, Perucca E, et al. Treatment of status epilepticus in adults: guidelines of the Italian League Against Epilepsy. *Epilepsia.* 2006;47(suppl 5):9-15.
32. Lahat E, Goldman M, Barr J, et al. Intranasal midazolam for childhood seizures. *Lancet.* 1998;352(9128):620.
33. Lahat E, Goldman M, Barr J, et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: Prospective randomised study. *BMJ.* 2000;321(7253):83-86.
34. Fisgin T, Gurer Y, Tezic T, et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. *J Child Neurol.* 2002;17(2):123-126.

35. Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. *Pediatr Neurol*. 2006;34(5):355-359.
36. Tonekaboni SH, Shamsabadi FM, Anvari SS, et al. A comparison of buccal midazolam and intravenous diazepam for the acute treatment of seizures in children. *Iran J Pediatr*. 2012;22(3):303-308.
37. Silbergleit R, Lowenstein D, Durkalski V, Conwit R. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. *Epilepsia*. 2011;52(suppl 8):45-47.
38. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. *N Engl J Med*. 2012;366(7):591-600.
39. Abou-Khalil B, Wheless J, Rogin J, et al. A double-blind, randomized, placebo-controlled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures. *Epilepsia*. 2013;54(11):1968-1976.
40. Rogin J, Wheless J, Abou-Khalil B, et al. Safety and effectiveness of long-term treatment with diazepam auto-injector administered by caregivers in an outpatient setting for the treatment of acute repetitive seizures. *Epilepsia*. 2014;55(9):1444-1451.
41. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: A randomised trial. *Lancet*. 1999;353(9153):623-626.
42. Camfield PR. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. *J Pediatr*. 1999;135(3):398-399.
43. Warden CR, Frederick C. Midazolam and diazepam for pediatric seizures in the prehospital setting. *Prehosp Emerg Care*. 2006;10(4):463-467.
44. Harbord MG, Kyrkou NE, Kyrkou MR, et al. Use of intranasal midazolam to treat acute seizures in paediatric community settings. *J Paediatr Child Health*. 2004;40(9-10):556-558.
45. Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. *Arch Pediatr Adolesc Med*. 2010;164(8):747-753.
46. O'Regan ME, Brown JK, Clarke M. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures? *Dev Med Child Neurol*. 1996;38(11):1037-1045.
47. Kutlu NO, Yakinci C, Dogrul M, Durmaz Y. Intranasal midazolam for prolonged convulsive seizures. *Brain Dev*. 2000;22(6):359-361.
48. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. *Epilepsy Behav*. 2004;5(2):253-255.
49. Holsti M, Sill BL, Firth SD, et al. Prehospital intranasal midazolam for the treatment of pediatric seizures. *Pediatr Emerg Care*. 2007;23(3):148-153.
50. Thakker A, Shanbag P. A randomized controlled trial of intranasal-midazolam versus intravenous-diazepam for acute childhood seizures. *J Neurol*. 2013;260(2):470-474.
51. McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. *Acad Emerg Med*. 2010;17(6):575-582.
52. Anderson M, Tambe P, Sammons H, et al. Pharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers. *Eur J Clin Pharmacol*. 2012;68(2):155-159.
53. Scheepers M, Scheepers B, Clarke M, et al. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? *Seizure*. 2000;9(6):417-422.
54. Rey E, Delaunay L, Pons G, et al. Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration. *Eur J Clin Pharmacol*. 1991;41(4):355-357.
55. Wermeling DP, Miller JL, Archer SM, et al. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. *J Clin Pharmacol*. 2001;41(11):1225-1231.
56. Arya R, Gulati S, Kabra M, et al. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. *Epilepsia*. 2011;52(4):788-793.

57. Fisgin T, Gurer Y, Senbil N, et al. Nasal midazolam effects on childhood acute seizures. *J Child Neurol*. 2000;15(12):833-835.
58. Anderson M. Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability. *Patient Prefer Adherence*. 2013;7:27-34.
59. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. *Lancet*. 2005;366(9481):205-210.
60. Mpimbaza A, Ndeezi G, Staedke S, et al. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. *Pediatrics*. 2008;121(1):e58-64.
61. Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. *Brain Dev*. 2009;31(10):744-749.
62. Khan A, Baheerathan A, Setty G, Hussain N. Carers' express positive views on the acceptability, efficacy and safety of buccal midazolam for paediatric status epilepticus. *Acta Paediatr*. 2014;103(4):e165-168.
63. Ivaturi V, Kriel R, Brundage R, et al. Bioavailability of intranasal vs. rectal diazepam. *Epilepsy Res*. 2013;103(2-3):254-261.
64. Malinovsky JM, Lejus C, Servin F, et al. Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. *Br J Anaesth*. 1993;70(6):617-620.
65. Knoester PD, Jonker DM, Van Der Hoeven RT, et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. *Br J Clin Pharmacol*. 2002;53(5):501-507.
66. Baysun S, Aydin OF, Atmaca E, Gurer YK. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. *Clin Pediatr (Phila)*. 2005;44(9):771-776.
67. Ashrafi MR, Khosroshahi N, Karimi P, et al. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. *Eur J Paediatr Neurol*. 2010;14(5):434-438.
68. Anderson GD, Saneto RP. Current oral and non-oral routes of antiepileptic drug delivery. *Adv Drug Deliv Rev*. 2012;64(10):911-918.
69. Humphries LK, Eiland LS. Treatment of acute seizures: Is intranasal midazolam a viable option? *J Pediatr Pharmacol Ther*. 2013;18(2):79-87.
70. Khan TM, Kissoon N, Hasan MY, et al. Comparison of plasma levels and pharmacodynamics after intraosseous and intravenous administration of fosphenytoin and phenytoin in piglets. *Pediatr Crit Care Med*. 2000;1(1):60-64.
71. Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. *Neurology*. 1988;38(2):202-207.
72. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative study group. *N Engl J Med*. 17 1998;339(12):792-798.
73. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. *Seizure*. 2014;23(3):167-174.
74. Limdi NA, Shimpi AV, Faught E, et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. *Neurology*. 2005;64(2):353-355.
75. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus—experience in 102 adult patients. *Seizure*. 2005;14(3):164-169.
76. Olsen KB, Tauboll E, Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. *Acta Neurol Scand Suppl*. 2007;187:51-54.
77. Gilad R, Izkovitz N, Dabby R, et al. Treatment of status epilepticus and acute repetitive seizures with I.V. Valproic acid vs phenytoin. *Acta Neurol Scand*. 2008;118(5):296-300.
78. Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. *Seizure*. 2007;16(6):527-532.

79. Chen L, Feng P, Wang J, et al. Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. *J Clin Neurosci*. 2009;16(4):524-526.
80. Hovinga CA, Chicella MF, Rose DF, et al. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. *Ann Pharmacother*. 1999;33(5):579-584.
81. Uberall MA, Trollmann R, Wunsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. *Neurology*. 2000;54(11):2188-2189.
82. Yu KT, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. *Epilepsia*. 2003;44(5):724-726.
83. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: A randomized controlled trial. *J Child Neurol*. 2007;22(10):1191-1197.
84. Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: A pilot study. *Neurology*. 2006;67(2):340-342.
85. Tiamkao S, Sawanyawisuth K, Chancha-roen A. The efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study. *BMC Neurol*. 2013;13:98.
86. Chitsaz A, Mehvari J, Salari M, et al. A comparative assessment the efficacy of intravenous infusion of sodium valproate and phenytoin in the treatment of status epilepticus. *Int J Prev Med*. 2013;4(Suppl 2):S216-221.
87. Malamiri RA, Ghaempanah M, Khosroshahi N, et al. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. *Eur J Paediatr Neurol*. 2012;16(5):536-541.
88. Brigo F, Storti M, Del Felice A, et al. IV valproate in generalized convulsive status epilepticus: a systematic review. *Eur J Neurol*. 2012;19(9):1180-1191.
89. Brigo F, Igwe SC, Nardone R, et al. A common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone for convulsive status epilepticus. *Epileptic Disord*. 2013;15(3):314-323.
90. Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. *Epilepsy Behav*. 2006;8(3):651-654.
91. Patel NC, Landan IR, Levin J, et al. The use of levetiracetam in refractory status epilepticus. *Seizure*. 2006;15(3):137-141.
92. Rupperecht S, Franke K, Fitzek S, et al. Levetiracetam as a treatment option in non-convulsive status epilepticus. *Epilepsy Res*. 2007;73(3):238-244.
93. Goraya JS, Khurana DS, Valencia I, et al. Intravenous levetiracetam in children with epilepsy. *Pediatr Neurol*. 2008;38(3):177-180.
94. Abend NS, Monk HM, Licht DJ, Dlugos DJ. Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. *Pediatr Crit Care Med*. 2009;10(4):505-510.
95. Kirmani BF, Crisp ED, Kayani S, Rajab H. Role of intravenous levetiracetam in acute seizure management of children. *Pediatr Neurol*. 2009;41(1):37-39.
96. Standish JC, Hilmas E, Falchek SJ. Levetiracetam for the treatment of pediatric status epilepticus: a case series. *J Pediatr Neurol*. 2011;9(2):195-201.
97. McTague A, Kneen R, Kumar R, et al. Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: Experience from a children's hospital. *Seizure*. 2012;21(7):529-534.
98. Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. *Epilepsia*. 2013;54(3):393-404.
99. Shiloh-Malawsky Y, Fan Z, Greenwood R, Tennison M. Successful treatment of childhood prolonged refractory status epilepticus with lacosamide. *Seizure*. 2011;20(7):586-588.
100. Jain V, Harvey AS. Treatment of refractory tonic status epilepticus with intravenous lacosamide. *Epilepsia*. 2012;53(4):761-762.
101. Temkin NR, Dikmen SS, Anderson GD, et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. *J Neurosurg*. 1999;91(4):593-600.

102. Gerstner T, Teich M, Bell N, et al. Valproate-associated coagulopathies are frequent and variable in children. *Epilepsia*. 2006;47(7):1136-1143.
103. Embacher N, Karner E, Wanschitz J, et al. Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus. *Eur J Neurol*. 2006;13(10):e5-6.
104. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? *Epilepsy Behav*. 2011;20(1):20-23.
105. Bleck T, Cock H, Chamberlain J, et al. The established status epilepticus trial 2013. *Epilepsia*. 2013;54(suppl 6):89-92.
106. Shinnar S, Pellock JM, Moshe SL, et al. In whom does status epilepticus occur: age-related differences in children. *Epilepsia*. 1997;38(8):907-914.
107. Wu YW, Shek DW, Garcia PA, et al. Incidence and mortality of generalized convulsive status epilepticus in California. *Neurology*. 9 2002;58(7):1070-1076.
108. Moshe SL. Brain injury with prolonged seizures in children and adults. *J Child Neurol*. 1998;13(suppl 1):S3-S6; discussion S30-32.
109. Sahin M, Menache CC, Holmes GL, Riviello JJ, Jr. Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children. *Neurology*. 12 2003;61(3):398-401.
110. Maytal J, Shinnar S, Moshe SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. *Pediatrics*. 1989;83(3):323-331.
111. Gilbert DL, Gartside PS, Glauser TA. Efficacy and mortality in treatment of refractory generalized convulsive status epilepticus in children: a meta-analysis. *J Child Neurol*. 1999;14(9):602-609.
112. Sahin M, Menache CC, Holmes GL, Riviello JJ. Outcome of severe refractory status epilepticus in children. *Epilepsia*. 2001;42(11):1461-1467.
113. Kim SJ, Lee DY, Kim JS. Neurologic outcomes of pediatric epileptic patients with pentobarbital coma. *Pediatr Neurol*. 2001;25(3):217-220.
114. Fountain NB, Fugate JE. Refractory status epilepticus: what to put down: the anesthetics or the patient? *Neurology*. 25 2014;82(8):650-651.
115. Claassen J, Hirsch LJ, Mayer SA. Treatment of status epilepticus: a survey of neurologists. *J Neurol Sci*. 15 2003;211(1-2):37-41.
116. Holtkamp M, Masuhr F, Harms L, et al. The management of refractory generalised convulsive and complex partial status epilepticus in three European countries: a survey among epileptologists and critical care neurologists. *J Neurol Neurosurg Psychiatry*. 2003;74(8):1095-1099.
117. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. *Epilepsia*. 2002;43(2):146-153.
118. Young RS, Ropper AH, Hawkes D, et al. Pentobarbital in refractory status epilepticus. *Pediatr Pharmacol (New York)*. 1983;3(2):63-67.
119. Lowenstein DH, Aminoff MJ, Simon RP. Barbiturate anesthesia in the treatment of status epilepticus: Clinical experience with 14 patients. *Neurology*. 1988;38(3):395-400.
120. Rashkin MC, Youngs C, Penovich P. Pentobarbital treatment of refractory status epilepticus. *Neurology*. 1987;37(3):500-503.
121. Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. *Neurology*. 1993;43(5):895-900.
122. Kinoshita H, Nakagawa E, Iwasaki Y, et al. Pentobarbital therapy for status epilepticus in children: Timing of tapering. *Pediatr Neurol*. 1995;13(2):164-168.
123. Holmes GL, Riviello JJ Jr. Midazolam and pentobarbital for refractory status epilepticus. *Pediatr Neurol*. 1999;20(4):259-264.
124. Barberio M, Reiter PD, Kaufman J, et al. Continuous infusion pentobarbital for refractory status epilepticus in children. *J Child Neurol*. 2012;27(6):721-726.
125. Mirski MA, Williams MA, Hanley DF. Prolonged pentobarbital and phenobarbital coma for refractory generalized status epilepticus. *Crit Care Med*. 1995;23(2):400-404.

126. Lee WK, Liu KT, Young BW. Very-high-dose phenobarbital for childhood refractory status epilepticus. *Pediatr Neurol*. 2006;34(1):63-65.
127. Osorio I, Reed RC. Treatment of refractory generalized tonic-clonic status epilepticus with pentobarbital anesthesia after high-dose phenytoin. *Epilepsia*. 1989;30(4):464-471.
128. Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. *Epilepsia*. 1996;37(9):863-867.
129. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: Effect of treatment aggressiveness on prognosis. *Arch Neurol*. 2005;62(11):1698-1702.
130. Schreiber JM, Gaillard WD. Treatment of refractory status epilepticus in childhood. *Curr Neurol Neurosci Rep*. 2011;11(2):195-204.
131. Van Ness PC. Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. *Epilepsia*. 1990;31(1):61-67.
132. Chicella M, Jansen P, Parthiban A, et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. *Crit Care Med*. 2002;30(12):2752-2756.
133. Bledsoe KA, Kramer AH. Propylene glycol toxicity complicating use of barbiturate coma. *Neurocrit Care*. 2008;9(1):122-124.
134. Miller MA, Forni A, Yogaratnam D. Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital. *Ann Pharmacother*. 2008;42(10):1502-1506.
135. Barnes BJ, Gerst C, Smith JR, et al. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. *Pharmacotherapy*. 2006;26(1):23-33.
136. Parker MG, Fraser GL, Watson DM, Riker RR. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. *Intensive Care Med*. 2002;28(1):81-84.
137. Zar T, Yusufzai I, Sullivan A, Graeber C. Acute kidney injury, hyperosmolality and metabolic acidosis associated with lorazepam. *Nat Clin Pract Nephrol*. 2007;3(9):515-520.
138. Rivera R, Segnini M, Baltodano A, Perez V. Midazolam in the treatment of status epilepticus in children. *Crit Care Med*. 1993;21(7):991-994.
139. Koul RL, Raj Aithala G, Chacko A, et al. Continuous midazolam infusion as treatment of status epilepticus. *Arch Dis Child*. 1997;76(5):445-448.
140. Igartua J, Silver P, Maytal J, Sagy M. Midazolam coma for refractory status epilepticus in children. *Crit Care Med*. 1999;27(9):1982-1985.
141. Ozdemir D, Gulez P, Uran N, et al. Efficacy of continuous midazolam infusion and mortality in childhood refractory generalized convulsive status epilepticus. *Seizure*. 2005;14(2):129-132.
142. Morrison G, Gibbons E, Whitehouse WP. High-dose midazolam therapy for refractory status epilepticus in children. *Intensive Care Med*. 2006;32(12):2070-2076.
143. Koul R, Chacko A, Javed H, Al Riyami K. Eight-year study of childhood status epilepticus: Midazolam infusion in management and outcome. *J Child Neurol*. 2002;17(12):908-910.
144. Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. *J Child Neurol*. 2002;17(2):106-110.
145. Hayashi K, Osawa M, Aihara M, et al. Efficacy of intravenous midazolam for status epilepticus in childhood. *Pediatr Neurol*. 2007;36(6):366-372.
146. Claassen J, Hirsch LJ, Emerson RG, et al. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. *Neurology*. 25 2001;57(6):1036-1042.
147. Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. *Brain*. 2012;135(Pt 8):2314-2328.
148. Fernandez A, Lantigua H, Lesch C, et al. High-dose midazolam infusion for refractory status epilepticus. *Neurology*. 28 2014;82(4):359-365.
149. Wilkes R, Tasker RC. Pediatric intensive care treatment of uncontrolled status epilepticus. *Crit Care Clin*. 2013;29(2):239-257.

150. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. *Crit Care Med*. 1992;20(4):483-488.
151. Naritoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. *Neurology*. 2000;54(6):1366-1368.
152. Harrison AM, Lugo RA, Schunk JE. Treatment of convulsive status epilepticus with propofol: case report. *Pediatr Emerg Care*. 1997;13(6):420-422.
153. Brown LA, Levin GM. Role of propofol in refractory status epilepticus. *Ann Pharmacother*. 1998;32(10):1053-1059.
154. Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: A study of 31 episodes. *Epilepsia*. 2004;45(7):757-763.
155. Parviainen I, Uusaro A, Kalviainen R, et al. Propofol in the treatment of refractory status epilepticus. *Intensive Care Med*. 2006;32(7):1075-1079.
156. Rossetti AO, Milligan TA, Vulliemoz S, et al. A randomized trial for the treatment of refractory status epilepticus. *Neurocrit Care*. 2011;14(1):4-10.
157. van Gestel JP, Blusse van Oud-Alblas HJ, Malingre M, et al. Propofol and thiopental for refractory status epilepticus in children. *Neurology*. 2005;65(4):591-592.
158. Timpe EM, Eichner SF, Phelps SJ. Propofol-related infusion syndrome in critically ill pediatric patients: Coincidence, association, or causation? *J Pediatr Pharmacol Ther*. 2006;11(1):17-42.
159. Barclay K, Williams AJ, Major E. Propofol infusion in children. *BMJ*. 1992;305(6859):953; author reply 953-954.
160. Cray SH, Robinson BH, Cox PN. Lactic acidemia and bradyarrhythmia in a child sedated with propofol. *Crit Care Med*. 1998;26(12):2087-2092.
161. Wolf A, Weir P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. *Lancet*. 24 2001;357(9256):606-607.
162. Withington DE, Decell MK, Al Ayed T. A case of propofol toxicity: Further evidence for a causal mechanism. *Paediatr Anaesth*. 2004;14(6):505-508.
163. Culp KE, Augoustides JG, Ochroch AE, Milas BL. Clinical management of cardiogenic shock associated with prolonged propofol infusion. *Anesth Analg*. 2004;99(1):221-226.
164. Guitton C, Gabillet L, Latour P, et al. Propofol infusion syndrome during refractory status epilepticus in a young adult: Successful ECMO resuscitation. *Neurocrit Care*. 2011;15(1):139-145.
165. Mayette M, Gonda J, Hsu JL, Mihm FG. Propofol infusion syndrome resuscitation with extracorporeal life support: A case report and review of the literature. *Ann Intensive Care*. 2013;3(1):32.
166. Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. *Crit Care Med*. 2009;37(12):3024-3030.
167. Baumeister FA, Oberhoffer R, Liebhaber GM, et al. Fatal propofol infusion syndrome in association with ketogenic diet. *Neuroepidemiology*. 2004;35(4):250-252.
168. Voss LJ, Sleigh JW, Barnard JP, Kirsch HE. The howling cortex: seizures and general anesthetic drugs. *Anesth Analg*. 2008;107(5):1689-1703.
169. Walder B, Tramer MR, Seck M. Seizure-like phenomena and propofol: a systematic review. *Neurology*. 2002;58(9):1327-1332.
170. Zubair S, Patton T, Smithson K, et al. Propofol withdrawal seizures: Non-epileptic nature of seizures in a patient with recently controlled status epilepticus. *Epileptic Disord*. 2011;13(1):107-110.
171. Dorandeu F, Dhote F, Barbier L, et al. Treatment of status epilepticus with ketamine, are we there yet? *CNS Neurosci Ther*. 2013;19(6):411-427.
172. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. *Neurology*. 1998;51(6):1765-1766.
173. Rosati A, L'Erario M, Ilvento L, et al. Efficacy and safety of ketamine in refractory status epilepticus in children. *Neurology*. 2012;79(24):2355-2358.
174. Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. *Epilepsia*. 2013;54(8):1498-1503.

175. Gofrit ON, Leibovici D, Shemer J, et al. Ketamine in the field: The use of ketamine for induction of anaesthesia before intubation in injured patients in the field. *Injury*. 1997;28(1):41-43.
176. Kofke WA, Young RS, Davis P, et al. Isoflurane for refractory status epilepticus: a clinical series. *Anesthesiology*. 1989;71(5):653-659.
177. Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. *Arch Neurol*. 2004;61(8):1254-1259.
178. Fugate JE, Burns JD, Wijdicks EF, et al. Prolonged high-dose isoflurane for refractory status epilepticus: Is it safe? *Anesth Analg*. 2010;111(6):1520-1524.
179. Visser NA, Braun KP, Leijten FS, et al. Magnesium treatment for patients with refractory status epilepticus due to polg1-mutations. *J Neurol*. 2011;258(2):218-222.
180. Kahriman M, Minecan D, Kutluay E, et al. Efficacy of topiramate in children with refractory status epilepticus. *Epilepsia*. 2003;44(10):1353-1356.
181. Blumkin L, Lerman-Sagie T, Houry T, et al. Pediatric refractory partial status epilepticus responsive to topiramate. *J Child Neurol*. 2005;20(3):239-241.
182. Akyildiz BN, Kumandas S. Treatment of pediatric refractory status epilepticus with topiramate. *Childs Nerv Syst*. 2011;27(9):1425-1430.
183. Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. *Epilepsia*. 2006;47(6):1070-1071.
184. Bragatti JA, Torres CM, Netto CB, et al. Topiramate is effective for status epilepticus and seizure control in neuraminidase deficiency. *Arq Neuropsiquiatr*. 2011;69(3):565-566.
185. Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. *Epilepsia*. 2001;42(3):387-392.
186. Ozer Y, Altunkaya H. Topiramate induced metabolic acidosis. *Anaesthesia*. 2004;59(8):830.
187. Fakhoury T, Murray L, Seger D, et al. Topiramate overdose: clinical and laboratory features. *Epilepsy Behav*. 2002;3(2):185-189.
188. Lynch MJ, Pizon AF, Siam MG, Krasowski MD. Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. *J Med Toxicol*. 2010;6(2):135-138.
189. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: A critical review of available therapies and a clinical treatment protocol. *Brain*. 2011;134(Pt 10):2802-2818.
190. Wheless JW. Treatment of refractory convulsive status epilepticus in children: other therapies. *Semin Pediatr Neurol*. 2010;17(3):190-194.
191. Rogawski MA, Loya CM, Reddy K, et al. Neuroactive steroids for the treatment of status epilepticus. *Epilepsia*. 2013;54(suppl 6):93-98.
192. Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in rasmussen's encephalitis. *Neurology*. 2003;61(12):1807-1810.
193. Gall CR, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (Norse) syndrome: outcomes with early immunotherapy. *Seizure*. 2013;22(3):217-220.
194. Schmitt FC, Buchheim K, Meierkord H, Holtkamp M. Anticonvulsant properties of hypothermia in experimental status epilepticus. *Neurobiol Dis*. 2006;23(3):689-696.
195. Orłowski JP, Erenberg G, Lueders H, Cruse RP. Hypothermia and barbiturate coma for refractory status epilepticus. *Crit Care Med*. 1984;12(4):367-372.
196. Corry JJ, Dhar R, Murphy T, Diringner MN. Hypothermia for refractory status epilepticus. *Neurocrit Care*. 2008;9(2):189-197.
197. Rossetti AO. What is the value of hypothermia in acute neurologic diseases and status epilepticus? *Epilepsia*. 2011;52(suppl 8):64-66.
198. Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome p450 enzyme system. *Crit Care Med*. 2007;35(9):2196-2204.
199. Empey PE, de Mendizabal NV, Bell MJ, et al. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. *Crit Care Med*. 2013;41(10):2379-2387.

200. Weiner RD, Coffet CE, Fochtmann L. *The Practice of ECT: Recommendations for Treatment, Training and Privileging*. 2nd ed. Washington, DC: American Psychiatric Press; 2001.
201. Sackeim HA. The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. *J ECT*. 1999;15(1):5-26.
202. Lambrecq V, Villega F, Marchal C, et al. Refractory status epilepticus: electroconvulsive therapy as a possible therapeutic strategy. *Seizure*. 2012;21(9):661-664.
203. Cervenka MC, Hartman AL, Venkatesan A, et al. The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit. *Neurocrit Care*. 2011;15(3):519-524.
204. Cobo NH, Sankar R, Murata KK, et al. The ketogenic diet as broad-spectrum treatment for super-refractory pediatric status epilepticus: challenges in implementation in the pediatric and neonatal intensive care units. *J Child Neurol*. 2014.
205. Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). *Epilepsia*. 2010;51(10):2033-2037.
206. Nam SH, Lee BL, Lee CG, et al. The role of ketogenic diet in the treatment of refractory status epilepticus. *Epilepsia*. 2011;52(11):e181-184.
207. Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super-refractory status epilepticus. *Neurology*. 2014;82(8):665-670.
208. Winston KR, Levisohn P, Miller BR, Freeman J. Vagal nerve stimulation for status epilepticus. *Pediatr Neurosurg*. 2001;34(4):190-192.
209. Patwardhan RV, Dellabadia J, Jr., Rashidi M, et al. Control of refractory status epilepticus precipitated by anticonvulsant withdrawal using left vagal nerve stimulation: a case report. *Surg Neurol*. 2005;64(2):170-173.
210. O'Neill BR, Valeriano J, Synowiec A, et al. Refractory status epilepticus treated with vagal nerve stimulation: case report. *Neurosurgery*. 2011;69(5):E1172-1175.
211. Hauptman JS, Mathern GW. Vagal nerve stimulation for pharmacoresistant epilepsy in children. *Surg Neurol Int*. 2012;3(suppl 4):S269-274.
212. Rossignol E, Lortie A, Thomas T, et al. Vagus nerve stimulation in pediatric epileptic syndromes. *Seizure*. 2009;18(1):34-37.